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ABSTRACT 
Pyruvate dehydrogenase phosphatase (PDP) regulates carbohydrate oxidation through the 
pyruvate dehydrogenase (PDH) complex. PDP activates PDH, enabling increased 
carbohydrate flux towards oxidative energy production. In culture myoblasts, both PDP1 
and PDP2 undergo covalent activation in response to insulin–stimulation by protein 
kinase C delta (PKCδ). Our objective was to examine the effect of insulin on PDP 
phosphorylation and PDH activation in skeletal muscle. Intact rat extensor digitorum 
longus muscles were incubated (oxygenated at 25°C, 1g of tension) for 30min in basal or 
insulin–stimulated (10 mU/mL) media. PDH activity increased 58% following 
stimulation, (p=0.057, n=11). Serine phosphorylation of PDP1 (p=0.047) and PDP2 
(p=0.006) increased by 29% and 48%, respectively (n=8), and mitochondrial PKCδ 
protein content was enriched by 45% in response to stimulation (p=0.0009, n=8). These 
data suggest that the insulin–stimulated increase in PDH activity in whole tissue is 
mediated through mitochondrial migration of PKCδ and subsequent PDP phosphorylation. 
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CHAPTER 1: 
 
INTRODUCTION 
 Pyruvate dehydrogenase (PDH) is a tightly regulated mitochondrial multi–enzyme 
complex that plays an important role in skeletal muscle metabolism. The relative balance 
of energy expended to accomplish any physical task depends upon the fuel partitioning of 
three major sources: carbohydrates (CHO), fat and protein. Every physical task involves 
unique energy requirements, and all require energy that is primarily recruited from one of 
these sources. For example, activities of maximal intensity predominantly utilize CHO 
stores, whereas exercise characterized by light and moderate intensities relies more 
heavily on fat stores (Howlett et al., 1998). The amount of energy we utilize from each 
energy source is known as fuel partitioning, which is determined by complex metabolic 
demands (as reviewed by Harris, Bowker–Kinley, Huang, & Wu, 2002). As the largest 
organ in the human body, skeletal muscle tissue is one site of focal importance with 
respect to CHO and fat oxidation (Proctor, O’Brien, Atkinson, & Nair, 1999). The PDH 
complex regulates the relative contribution of carbohydrate stores towards energy 
provision. Consequently, regulation of the PDH complex in skeletal muscle has major 
implications towards glucose disposal as well as whole body glucose homeostasis. PDH 
regulation is accomplished by the overall activities of two phosphatases (PDP1 & PDP2; 
PDH upregulation via dephosphorylation) and four kinases (PDK 1–4; PDH down 
regulation via phosphorylation). PDP and PDK contents and activities are subject to 
adaptation in response to metabolic perturbation. This thesis serves to investigate the 
effects of insulin stimulation upon the covalent activation of both PDP isoforms, and by 
extension PDH activation, in intact rat extensor digitorum longus skeletal muscle tissue. 
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LITERATURE REVIEW 
Pyruvate Dehydrogenase: The Background 
 The role of the pyruvate dehydrogenase (PDH) complex is to determine and 
regulate overall whole–body carbohydrate oxidation. This enzyme complex is the link 
between glycolysis and the tricarboxylic acid (TCA) cycle in every cell containing 
mitochondria (Harris et al., 2002). Furthermore, PDH is responsible for appropriating the 
rate of oxidative phosphorylation and subsequent ATP production from carbohydrate 
derived carbon sources (Putman et al., 1993). Whether one is participating in high–
intensity exercise or simply thinking, carbohydrate–derived energy is being used at 
different rates. The role of the active pyruvate dehydrogenase complex (PDHa) is to 
assist in meeting such varied metabolic demands, amongst cooperative energy production 
pathways (e. g. beta oxidation). PDH controls the flux of carbohydrate–derived acetyl–
CoA into the TCA cycle, thereby determining the rate of activity for the complex towards 
oxidative metabolism (Howlett et al., 1998, Putman et al., 1993). Pathways do exist for 
glucose to be metabolized non–oxidatively, such as gluconeogenesis or lactate production 
(Chokkalingam et al., 2007), but metabolism involving the PDH complex specifically 
leads to oxidative CHO utilization (Howlett et al., 1998, Putman et al., 1993). Although 
acetyl–CoA production stems from multiple pathways, the PDH complex produces 
acetyl–CoA from pyruvate, which is a metabolic intermediate made from glucose stores 
through glycolysis (Putman et al., 1993). 
 The stoichiometry of the basic pyruvate dehydrogenase reaction can be 
summarized as follows: 
Pyruvate + NAD+ + CoA   PDH   Acetyl–CoA + NADH + CO2 
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This reaction illustrates the irreversible oxidative decarboxylation of pyruvate to form 
acetyl–CoA (Smolle & Lindsay, 2006; Spriet & Heigenhauser, 2002). Occurring in the 
mitochondria, three–carbon pyruvate molecules are catabolized into two–carbon acetyl–
CoA molecules, including the release of the reducing equivalent nicotinamide adenine 
dinucleotide (NADH), and the production of carbon dioxide (Smolle & Lindsay, 2006; 
Spriet & Heigenhauser, 2002). From a chemistry standpoint, decarboxylation is 
significant because once a carbon is removed and released as gaseous carbon dioxide, it 
cannot be re–fixed to its predecessor. As a result, the three–carbon intermediate derived 
from glucose cannot be replaced. Furthermore, this alteration to the structure of pyruvate 
represents a noteworthy physiological commitment, as these two–carbon compounds are 
now fully committed towards oxidation. Such carbohydrate sources are now unavailable 
to be integrated other metabolic processes that require three–carbon molecules, such as 
gluconeogenesis (Spriet & Heigenhauser, 2002). 
The basic PDH reaction features a set of three individual reactions that take place 
within the mitochondrial matrix, as the PDH complex is believed to be located in close 
proximity to the cristae of the inner mitochondrial membrane (Margineantu, R. Brown, G. 
Brown, Marcus, & Capaldi, 2002; Schnaitman & Greenawalt, 1968). Each of the three 
reactions involves different subunits within the complex. The first reaction is a key 
irreversible step through a non–equilibrium, rate limiting enzyme (Smolle & Lindsay, 
2006; Spriet & Heigenhauser, 2002). Due to the nature of this enzyme classification, 
there is no metabolic pathway to reproduce glucose from acetyl–CoA stores, echoing 
previous statements regarding commitment to oxidation. The PDH complex functions 
uni–directionally and literally traps its products within the inner membrane of the 
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mitochondria (Spriet & Heigenhauser, 2002; Smolle & Lindsay, 2006). On the contrary, 
downstream reactions within the PDH complex (reactions 2 and 3) involve near–
equilibrium enzymes, which process substrates according to the law of mass action. In 
these instances, directionality is dependent upon an accumulation of substrate on either 
side of the reaction. To summarize the basic reaction, PDH alters the chemical structure 
of metabolic intermediates through uni–directional processing in order to commit 
carbohydrates towards oxidative metabolism. 
In order to specifically meet demand for carbohydrate oxidation, the PDH 
complex is capable of establishing varying levels of activity. Increased PDH complex 
activity is observed when dietary carbohydrate intake is relatively high (Putman et al., 
1993). In contrast, when dietary carbohydrate intake is low (as seen during fasting, 
starvation, and high–fat diet implementation), PDH activity is decreased (LeBlanc, Harris, 
& Peters, 2007; Pehleman, Peters, Heigenhauser, & Spriet, 2005). When PDH activity is 
down–regulated, acetyl–CoA substrate for the TCA cycle is produced through alternate 
energy production pathways (Harris et al., 2002). Beyond dietary perturbations, 
conditions do exist in which the body needs to conserve carbohydrates. When necessary, 
PDH activity will adjust accordingly. As an example, brain and nervous tissues require a 
constant supply of glucose in order to maintain functioning levels that cannot drop below 
a certain threshold (Harris et al., 2002). As a result, this scenario makes the conservation 
of endogenous carbohydrates a physiological priority. In the event that carbohydrate 
stores are depleted or dietary carbohydrate intake is low, carbohydrate oxidation in 
peripheral body tissues will be reduced (Harris et al., 2002). 
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Skeletal muscle is an exemplary tissue where PDH regulation is a high priority. 
By virtue of its total mass, skeletal muscle is the largest organ as well as the largest site of 
glucose disposal in the body (Stump, Henriksen, Wei, & Sowers, 2006). When 
carbohydrate stores and glucose homeostasis require maintenance, skeletal muscle is an 
example of a tissue that can readily adjust the PDH activity state in order to satisfy 
metabolic requirements. Scenarios also exist where there is a need to increase 
carbohydrate oxidation. In situations requiring large increases in energy provision, such 
as physical activity, intercellular communication will promote increased PDH activity 
proportional to exercise intensity and energy demand (Howlett et al., 1998). 
The PDH complex is situated at a major metabolic junction in the mitochondria, 
and its continuum of activity is grand in scope. PDH can be rapidly activated in order to 
support physical activity, and can also be silenced in order to address basic metabolic 
needs. PDH is present in numerous tissues throughout the body, and therefore possesses 
great influence over whole body glucose homeostasis. Thus, especially in tissues with 
metabolic plasticity such as skeletal muscle, tight regulation of the PDH complex is a 
major metabolic priority. 
PDH: Structural & Functional Synergy 
 The PDH complex is comprised of three distinct enzyme subunits: E1 (consisting 
of alpha & beta monomers), E2 and E3, which combine for a total weight of 9500 kDa 
(Harris et al., 2002). The PDH subunits catalyze mutually dependent individual reactions 
in a coordinated manner (Jilka, Rahmatullah, Kazemi, & Roche, 1986). Furthermore, it 
appears as if the function of the PDH complex is entirely dependent upon the spatial 
relationships between these three entities. The focal component underlying the structure 
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of each PDH complex is a three–dimensional core, which consists of roughly 60 E2 
subunit proteins in a pentagonal dodecahedron chemical structure (Hiromasa, Fujisawa, 
Aso, & Roche, 2004; Smolle & Lindsay, 2006). However, further analysis has generated 
speculation regarding the distribution of E2 subunits within this core. Studies have 
reported that the number of E2 subunits may be 48 (Hiromasa et al., 2004) or 40 
(Brautigam, Wynn, J. Chuang, & D. Chuang, 2009). Stemming from each respective E2 
protein within this core are two free–swinging lipoyl arms (jointly known as a “super 
arm”), which anchor the remaining enzymes within the complex (Harris et al., 2002; 
Patel & Roche, 1990). Core attachment through the lipoyl arms enables E1 and E3 
enzymes to move and fold with dynamic fluidity. This latter characteristic greatly 
enhances physical interaction and communication within the entire PDH complex 
(Smolle & Lindsay, 2006). Based upon this fundamental structure, E2 subunits provide 
the blueprint for which the remaining components of the complex depend upon for 
stability and reliable activity. 
 The PDH complex super arm consists of two lipoyl arms, however it is significant 
to note the presence of three uniform lipoyl domains within the super arm (Harris et al., 
2002). All three lipoyl domains are roughly 80 amino acids in length, and are directly 
responsible for anchoring all bound members of the complex in proper position (Patel & 
Roche, 1990; Smolle & Lindsay, 2006). For example, all E1 subunits bind to the E2 core 
at an E1 binding site that is common to all PDH complexes in mitochondria. 
Subsequently, this binding site is anchored by a lateral lipoyl domain (lipoyl domain A), 
which is located directly adjacent along one lipoyl arm of the collective super arm 
(Smolle & Lindsay, 2006). Furthermore, a secondary yet absolutely critical feature of 
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lipoyl domain A is that it houses binding sites for the primary regulatory proteins (kinases 
and phosphatases) of the PDH complex (Harris et al., 2002). These regulatory proteins 
are major players with respect to establishing conformational changes that establish 
appropriate PDH complex activity levels (a dynamic concept to be discussed later). 
A second lipoyl domain (lipoyl domain B) is responsible for double duty, as it 
anchors both the E1 binding site and lipoyl domain A (Smolle & Lindsay, 2006). Lipoyl 
domains A and B comprise one of the two free–swinging lipoyl arms (Harris et al., 2002). 
These three zones are oriented in a linear fashion with respect to the E2 core (as a point 
of reference), where each domain receives support from its distal counterpart in series. 
The final lipoyl domain (lipoyl domain C) exhibits the same general characteristic 
as domains A and B. Domain C is responsible for anchoring the final member of the PDH 
complex, the E3 enzyme. However, the structural relationship between E3 subunits and 
the E2 core involves the presence of a non–catalytic E3 binding protein (E3BP) (Harris et 
al., 2002; Jilka et al., 1986; Smolle & Lindsay, 2006). E3BP is responsible for the 
chemical connection between E3 subunits and the E2 core, and typical mammalian PDH 
complexes contain E3 and E3BP subunits in equal concentrations (Hiromasa et al., 2004). 
Furthermore, lipoyl domain C is unique in the sense that it is the only domain on the 
second free–swinging lipoyl arm. 
In summary, it is generally believed that the PDH complex super arm consists of 
two lipoyl arms. One of the two lipoyl arms contains lipoyl domains A and B that serve 
to anchor the E1 subunit and the PDH regulatory enzymes, and the second arm contains 
lipoyl domain C, which serves to anchor the E3 subunit, and an E3 binding protein 
(Harris et al., 2002; Smolle & Lindsay, 2006). This structure clearly defines each 
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respective member of the PDH complex as organized components of a mapped sequence 
to facilitate essential interaction and regulation within the complex. 
 
Figure 1. Structure of the mitochondrial PDH complex (Harris et al., 2002). 
PDH: Individual Reactions 
 A defining characteristic of the PDH complex is that proper functioning always 
relates back to fundamental structure. All binding domains and lipoyl domains are 
interconnected to neighbouring components within the complex by a series of proline and 
alanine rich amino acid chains of approximately 30 amino acids in length (Harris et al., 
2002; Smolle & Lindsay, 2006). The purpose of these chain links is to render the super 
arm more flexible, in order to enable lipoyl arm mobility (Smolle & Lindsay, 2006). The 
functional fluidity of the lipoyl arms is crucial to the overall efficiency and economy of 
the PDH complex. It is this multilateral action that enhances the proper relay of all 
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metabolic intermediates produced by individual E1, E2 and E3 reactions (Patel & Roche, 
1990; Smolle & Lindsay, 2006). 
 The E1 enzyme (pyruvate dehydrogenase) is a heterotetramer that is composed of 
4 monomer units (2 alpha and 2 beta), with an active site located at the interface of these 
components (Harris et al., 2002). In the presence of the cofactor thiamine diphosphate, E1 
is responsible for the decarboxylation of three–carbon pyruvate molecules, leading to the 
production of two–carbon acetyl intermediates and carbon dioxide (Gutowski & Lienhard, 
1976; Robinson & Chun, 1993; Smolle & Lindsay, 2006). This is the only non–
equilibrium reaction within the PDH reactions, which distinguishes this step as the 
primary regulator of aerobic carbohydrate flux. The E2 enzyme (dihydrolipoyl 
transacetylase) is responsible for the production and release of acetyl–CoA, coupling the 
two–carbon intermediates yielded from E1 with available free CoA within the 
mitochondrial matrix (Smolle & Lindsay, 2006). E2 subunits begin this redox reaction in 
an oxidized state, and are subsequently reduced by the acetyl group produced in the E1 
reaction to generate a stable intermediate. Now oxidized, the acetyl intermediate is 
reduced through combination with free CoA and released as acetyl–CoA. The E2 reaction 
is recognized as the source of working substrate for TCA cycle flux, as acetyl–CoA is the 
primary substrate of oxidative metabolism.  
The E2 subunit must be re–oxidized before reacting with another acetyl 
intermediate, and re–oxidation is accomplished through the last reaction in the PDH 
complex. The E3 enzyme (dihydrolipoyl dehydrogenase) is the energy–transferring 
reaction of the PDH complex (Patel & Roche, 1990; Smolle & Lindsay, 2006). This 
enzyme transfers electrons from flavin adenine dinucleotide (FADH2) to nicotinamide 
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adenine dinucleotide (NAD+) in order to produce NADH, which is the reduced form of 
NAD+ (Smolle & Lindsay, 2006; Yeaman, 1989). As a consequence, the E2 core is re–
oxidized, and one full cycle of the PDH reactions has been completed. All PDH complex 
subunits are now chemically prepared to accept more substrate. Unlike the first reaction 
involving E1, reactions two and three in this sequence are near–equilibrium reactions that 
depend on substrate channeling from upstream subunits within the complex. This 
observation further solidifies the notion that the E1 subunit catalyzes the rate limiting 
reaction of the PDH complex. 
 Although independent, all three reactions depend upon one another and this is 
illustrated by the manner in which their isolated functions extend to the complex as a 
whole. The E2 subunit is the central player in the PDH complex from a structural and 
functional standpoint, as this enzyme forms the core foundation for which E1 and E3 
moieties organize and execute their respective physiological functions (Harris et al., 
2002). 
 In order to promote the interaction of E1, E2 and E3 enzymes, the PDH complex 
relies upon a classic cross–bridging mechanism to couple all active sites (Smolle & 
Lindsay, 2006). Tight, non–covalent bonds exist between E1 and E2 enzymes, as well as 
E3 and E3BP subunits. However, the same cannot be said between E2 and E3 enzymes. 
These structural relationships are of particular significance, because in an instance where 
E1 is bound to E2, the E3 lipoyl arm is not bound to E2 due to steric hindrance, and vice 
versa (Smolle & Lindsay, 2006). Consequently, both lipoyl arms (anchoring E1 and E3) 
are free to shuttle within the complex and execute the necessary cross–bridging activity in 
order to claim space on available E2 active sites. 
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 It should be noted that E3BPs remain bound to isolated E2 subunits at all times, 
even when an E3 lipoyl domain is not interacting with and bound to E2 (Jilka et al., 1986). 
In fact, although a cohesive unit, E2 and E3BP are structurally distinct units (Jilka et al., 
1986). Furthermore, through analytical ultracentrifugation of isolated recombinant human 
PDH components, it has been shown that E3 subunits do not bind to E2 cores lacking E3 
binding proteins (Hiromasa et al., 2004). These findings strongly support the notion that 
E3BP is entirely responsible and available for the chemical connection between the E3 
subunit and the E2 core. 
This mechanism of activity is precisely what keeps the PDH complex moving at a 
predetermined rate (Yeaman, 1989). Physical interplay amongst the subunits is a direct 
application of the amino acid chain linkers, and highlights the importance of possessing 
free flowing lipoyl arms. Without such a defined structure, a regulatory function of this 
nature would not be possible. As a result, this synergistic mechanism allows for all 
metabolic intermediates produced within the complex to be shuttled for further 
catabolism as substrate for other enzymes within the complex (Smolle & Lindsay, 2006). 
The degree of chemical communication and networking seen in the PDH complex 
between glycolysis and oxidative metabolism is what opens the door for such tight 
regulation and management of carbohydrate stores. 
PDH: “Macro” Regulation 
 The PDH complex is a cooperative unit that functions under strict regulation. 
Control of the complex is completely dependent upon the metabolic demands that are 
experienced in given physical situations. Many physiological perturbations exist that 
promote regulatory signaling towards the complex (e.g., nutritional, physical activity) (as 
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reviewed by Peters, 2003). As a consequence of these conditions, regulation of the PDH 
complex is centrally focused around covalent regulation. The phosphorylation state of the 
complex is the major influence upon PDH activity, and it can be denoted that this method 
of regulation via phosphorylation and dephosphorylation as a system of coarse, or 
“macro-level” regulation. Furthermore, covalent regulation reconnects with the concept 
of fuel partitioning, as the specific activity level of the complex determines the degree to 
which acetyl–CoA production is driven by carbohydrate or fat metabolism (Harris et al., 
2002). 
 Covalent regulation of the PDH complex is accomplished by a series of four 
pyruvate dehydrogenase kinase isoforms (PDK1–4) (Bowker–Kinley, Davis, Wu, Harris, 
& Popov, 1998) and a pair of pyruvate dehydrogenase phosphatase isoforms (PDP1–2) 
(Huang et al., 1998). The relative activity of PDH regulatory enzymes in skeletal muscle 
is significant, as this tissue represents the greatest site for glucose disposal in the body 
(Stump et al., 2006). All regulatory proteins bind to the complex by way of lipoyl domain 
A, which is directly adjacent to the E1 subunit (Harris et al., 2002). Kinase enzymes bind 
to the complex as a dimer and attach phosphate molecules specifically to one of three 
serine residues on the alpha subunits of the E1 enzyme. The presence of tightly bound 
PDK causes interference in substrate channeling, leading to deactivation of the PDH 
complex (Harris et al., 2002). Moreover, it is the function of loosely bound phosphatase 
enzymes to reactivate the complex through dephosphorylation reactions (Smolle & 
Lindsay, 2006). Although E1 features alpha and beta subunits, it is only the alpha subunit 
that is a target for covalent modification (Yeaman et al., 1978). The relative activities of 
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the PDK and PDP enzymes determine the precise activity state of the PDH complex, and 
subsequent carbohydrate flux through oxidative metabolism (Harris et al., 2002). 
Through the mechanism of covalent regulation, it should be understood that PDH 
complexes are never fully active or inactive at any given time (Harris et al., 2002). In 
actuality, flux through the complex lies along a sensitive continuum ranging from high to 
low activity states. Summated PDK and PDP activity levels are reflected in this overall 
phosphorylation state (Sugden & Holness, 2003). In a relatively high phosphorylation 
state, PDH activity will be lower, thereby inhibiting carbohydrate oxidation. As a result, 
fat oxidation will be activated to a greater degree. In a relatively low phosphorylation 
state, the complex will be more open and active, which will lead to a higher reliance on 
carbohydrates. Ongoing changes that occur during physical activity or dietary 
perturbations subsequently effect and alter the phosphorylation state of the complex, 
leading to fluctuations in PDH activity levels (as reviewed by Peters, 2003). 
PDH: “Micro” Regulation 
There are numerous physiological scenarios that affect pyruvate dehydrogenase 
activity by altering the phosphorylation state of the complex. This range of metabolic 
states may be thought of as the “micro” level of PDH regulation. It is these metabolic 
states that exert a fine regulatory influence upon the regulatory enzymes controlling the 
overall phosphorylation state, or “macro” level, of organization. In general, a higher 
concentration of reaction products (e.g., acetyl–CoA, NADH) will cause increased PDK 
activity, resulting in decreased PDH complex activity. For example, high–fat feeding 
studies have demonstrated increased in acetyl–CoA production via beta–oxidation in 
order to conserve carbohydrate stores. Consequently, PDK activity is increased in order 
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to down–regulate PDH complex activity (Peters, 2003). Furthermore, a higher 
concentration of substrate (e.g., pyruvate, coenzyme A, NAD+) will cause decreased PDK 
activity, resulting in increased PDH complex activity (Yeaman, 1989). For example, 
physical activity causes increased glycolytic flux leading to increased pyruvate 
production, and pyruvate is a potent allosteric inhibitor of PDK activity (Peters, 2003). In 
the short term, with respect to acute regulation, PDH can be reversibly regulated by the 
influence of the complex’s chemical intermediates. A strong presence of acetyl–CoA or 
NADH will inhibit PDH flux though increased PDK activity, whereas high levels of free 
coenzyme A and NAD+ will antagonize this effect through increased PDP activity (as 
reviewed by Harris et al., 2002; Sugden & Holness, 2003). Another strong inhibitor of 
PDH phosphorylation by PDK is pyruvate. As the central working substrate of the PDH 
reaction, PDK activity is minimal and increased PDH flux will be observed when an 
abundance of this substrate is recruited for oxidation (Spriet & Heigenhauser, 2002). 
In relation to the structure of the PDH complex, PDK and PDP enzymes bind to 
the E2 core via lipoyl domain A, which is the inner lipoyl domain of the E1 lipoyl arm 
(Harris et al., 2002). Both regulatory enzymes bind at the same location, and it is the 
presence of one or the other that activates or inhibits active site coupling amongst the 
PDH subunits (as reviewed by Harris et al., 2002). There are three serine residues (sites 1, 
2 and 3) located in the E1–alpha (E1α) active site that are targeted for phosphorylation. 
Phosphorylation of these sites occurs in a specific order, where kinases target serine 
residue 1 first, followed by the 2nd and 3rd sites (Kolobova, Tuganova, Boulatnikov, & 
Popov, 2001). This tendency may be related to residue location, as sites 1 and 2 are 
located on the edge of the E1α active site and can be accessed more easily compared to 
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site 3, which is buried more deeply in the enzyme structure (as reviewed by Maj, 
Cameron, & Robinson, 2006). On the other hand, dephosphorylation via PDP can occur 
in random sequence with less specific tendencies (Kolobova et al., 2001). Beyond 
specific binding patterns, investigation has also revealed that phosphorylation at each 
serine residue can have varying effects within the complex.  Phosphorylation at site 1 is 
sufficient to fully inactivate the PDH complex. However, phosphorylation of sites 2 and 3 
demonstrate additional effects (Kolobova et al., 2001). The major function of site two is 
to promote PDH inactivation; however, this site also exhibits inhibitory effects toward 
PDH reactivation via PDP enzymes. The only role of serine residue 3 is to prevent 
reactivation via PDP (Kolobova et al., 2001). It is important to visualize that the E1 
binding domain (location of the E1α serine residues) is proximal to the E2 core relative to 
lipoyl domain A, which is where the regulatory enzymes PDK and PDP bind. This 
structural detail demonstrates that PDK and PDP work in a linear fashion that directly 
affects the interaction between adjacent E1 and E2 subunits of the PDH complex. Based 
upon this complex structure, we can gain a better understanding of how all PDH subunits 
interact in such an efficient manner. 
 All four isoenzymes of skeletal muscle PDK are able to phosphorylate the serine 
residues of the E1α subunit (Bowker–Kinley et al., 1998). The differing kinase 
isoenzymes have been distinguished by the numbers 1–4, as each isoform features its 
own set of unique characteristics. Although all four PDKs are capable of phosphorylating 
E1α serine residues, their specific roles in reference to PDH activity are still uncertain (as 
reviewed by Bowker–Kinley et al., 1998). Research has demonstrated varying patterns of 
allosteric regulation amongst the four PDKs, and this is demonstrated through unique 
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enzyme kinetics, allosteric activation and inhibition, phosphorylation site specificity, as 
well as tissue distribution in the body. 
 In a study completed by Bowker–Kinley et al. (1998), major tissue (heart, brain, 
spleen, liver, skeletal muscle, kidney, and the testes) distributions of all four PDK 
isoenzymes were determined through Northern blot analysis of messenger ribonucleic 
acid (mRNA) concentrations in rats. PDK1 was highly expressed in heart tissue, and was 
not found in any other major tissue in the body. A similar distribution pattern was noted 
for PDK3, as this enzyme was dominantly expressed in testes with extremely low and 
insignificant levels detected in other tissues. PDK4 was abundant in skeletal muscle and 
heart tissues, and weakly distributed in all other tissues. Lastly, PDK2 was found in every 
tissue tested, making this isoform the most ubiquitous and abundant. 
 Pertaining to PDK enzyme kinetics, Kolobova et al. (2001) conducted an in vitro 
study measuring the amount of phosphate incorporated from adenosine triphosphate 
(ATP) to PDH E1α serine residues in order to determine fundamental rates of activity for 
all four human recombinant PDK isoenzymes. PDK characteristics were determined by 
measuring phosphorylation rates through a direct molar relationship (mol/mol) between 
molecules of phosphate and molecules of the PDH E1 subunit. Through this method, it 
was determined that PDK1 was the most active isoform with the highest Vmax, 
incorporating 3.4 moles of phosphate from ATP per mol of E1. Under the same 
conditions PDK2, PDK3 and PDK4 reported measurements of 1.6 moles, 2.8 moles and 
2.6 moles, respectively (Kolobova et al., 2001). These numbers are of particular 
significance, as PDK enzymes appear to function according to a phenomenon known as 
‘half of the site’ reactivity. Every E1α subunit contains 3 serine residues, each with 2 
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sites for potential phosphorylation, which provides a total of 6 potential phosphorylation 
sites (Kolobova et al., 2001; Sugden & Holness, 2003). However, according to ‘half of 
the site’ reactivity, it was observed that the maximal number of phosphate molecules that 
could be incorporated in E1 was 3. Results from this study demonstrate that only PDK1, 
PDK3 and PDK4 follow this trend. PDK2 appears to be the only isoenzyme deviating 
from this principle, reporting a lower rate of activity of phosphate incorporation per mole 
of E1 (Kolobova et al., 2001). 
 Pyruvate is known to have a strong inhibitory influence on PDK activity. 
However, each isoform responds differently to this allosteric inhibition, which has 
revealed more information with regard to specific isoenzyme characteristics (Bowker–
Kinley et al., 1998). Synthetic dicholoroacetate (DCA) was tested in order to assess PDK 
inhibition by pyruvate, as this chemical is known to mimic the effect of pyruvate as a 
specific inhibitor of PDK activity (Bowker–Kinley et al., 1998). PDK2 responds very 
strongly to allosteric inhibition by pyruvate, as the addition of 0.2 mM of DCA was 
required to reduce PDK2 activity by half. PDK1 and PDK4 are less sensitive to inhibition 
by pyruvate, as they required 1 mM and 0.5 mM of DCA, respectively, in order to reduce 
activity levels by half. PDK3 was the only isoform that required a much higher 
concentration of DCA (8 mM) to exert the same influence upon this enzyme (Bowker–
Kinley et al., 1998). This finding is significant as it demonstrates the ability of PDK3 to 
contribute to the regulation of CHO oxidation in the presence of high glycolytic rates and 
high intracellular pyruvate concentrations. 
PDK1 appears to be the most powerful isoenzyme in the PDK family, yet PDK2 
is the most ubiquitous in rat tissue (Kolobova et al., 2001). Beyond these leading 
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characteristics, PDK4 is known to play a significant role specifically within skeletal 
muscle tissue (Bowker–Kinley et al., 1998). PDK3 appears to be the least understood 
member of the PDK family in skeletal muscle, primarily due to its extremely low mRNA 
concentration and protein expression. Another distinctive difference between all kinases 
is their serine site specificity for phosphorylation. For example, while all four PDKs are 
capable of phosphorylating serine residues 1 and 2, only PDK1 has demonstrated an 
ability to phosphorylate site 3 (Kolobova et al., 2001). This observation speaks highly to 
the potency of PDK1 towards inactivating the complex, as this isoform has shown the 
ability to incorporate phosphate at a rate 2–fold higher than PDK3 and PDK4, and 3–fold 
higher relative to PDK2.  
 Another noteworthy observation refers to the rates at which each serine residue is 
phosphorylated. Site 1 is the major PDH inactivating site, while sites 2 and 3 contribute 
less to inactivation and serve to prevent PDH reactivation by PDP (Kolobova et al., 2001). 
This pattern of activity is reflected in the activity rates of all kinases at each site. At site 1, 
PDK1 incorporated 2.9 moles of phosphate per mol of E1α, whereas PDK2, PDK3 and 
PDK4 incorporated an average of 1.5 moles of phosphate at site 1 (Kolobova et al., 2001). 
Furthermore, site 2 phosphorylation rates decreased to 2.8, 1.0, 1.6 and 1.7 mol/mol for 
PDK1, PDK2, PDK3 and PDK4 respectively, data that further characterizes PDK1 as the 
most active PDK isoform within the PDH complex. PDK2, PDK3 and PDK4 demonstrate 
enhanced site specificity relative to PDK1 through their decreased activity levels at all 
serine residues, and these trends have been reported previously. As reviewed by Maj et al. 
(2006), site specificity for site 1 is in the following order: PDK2 > PDK4 > PDK1 > 
PDK3. For site 2, specificity order is PDK3 > PDK4 > PDK2 > PDK1. Recall that these 
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are the two sites that all kinases can act upon, and based upon the established unique 
individual activity levels (with PDK1 exhibiting higher activity than all other PDKs), it is 
not surprising to notice PDK1 is at the lower end of the specificity spectrum for both 
phosphorylation sites. 
 The common ground connecting the two PDP isoenzymes is that they both require 
magnesium (Mg2+) for activity. However, PDP1 and PDP2 do have a sub–set of 
individual characteristics. In addition to Mg2+, PDP1 also requires calcium ions (Ca2+). In 
fact, the only way that PDP1 can bind to the PDH regulatory domain is through a 
chemical interaction requiring Ca2+ (Huang et al., 1998). Furthermore, calcium presence 
stimulates PDP1 activity as well by increasing the sensitivity of PDP1 to intracellular 
magnesium, leading to a 10–fold increased rate of activity (Huang et al., 1998). 
Furthermore, PDP1 is the only phosphatase to feature a regulatory subunit (PDPr). This 
regulatory molecule functions by blocking the PDP1 active site in order to compete with 
intracellular magnesium (Yan, Lawson, & Reed, 1996). In the event that an association 
with magnesium is prevented through competitive inhibition, PDP1 activity is inhibited. 
Therefore, PDP1 sensitivity towards magnesium is decreased through an inhibitory effect 
(Yan et al., 1996). 
 From a tissue distribution perspective, PDP1 is most abundantly expressed in the 
heart, brain, testes and skeletal muscle, and it is the dominant phosphatase enzyme in 
calcium–sensitive tissues, such as skeletal muscle and brain (Huang et al., 1998). The 
primary role of PDP enzymes is to stimulate the oxidation of carbohydrate sources for 
energy production; therefore, a significant presence of PDP1 in tissues that rely heavily 
upon CHO oxidation is logical. 
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 PDP2 does not require calcium in order to function, and it is typically targeted in 
metabolic scenarios involving nutritional or hormonal perturbations (as reviewed by 
Harris et al., 2002). PDP2 is highly expressed in adipose tissue, but is also expressed in 
the heart, kidneys and liver (Huang et al., 1998). Based upon the fact that this isoenzyme 
is not functionally dependent upon calcium ions, and does not feature a distinct 
regulatory component, we are led to believe that PDP2 is the less regulated isoenzyme of 
the PDP family. However, PDP2 has been shown to function at a rate of activity 50–fold 
lower than PDP1, potentially eliminating the need for fine–tuned regulation (as reviewed 
by Sugden & Holness, 2003). Although PDP2 features simpler enzyme kinetic and 
regulation, the presence of insulin is known to effect sensitivity towards magnesium, 
leading to increased enzyme activity (Caruso et al., 2001). 
Rationale: Evidence for the Covalent Regulation of PDP 
In the past decade, the literature has demonstrated considerable evidence 
implicating additional regulatory mechanisms of PDP enzymes in skeletal muscle tissue. 
Pertinent studies focused on these explicitly suggest covalent modification as a regulator 
of in vivo PDP activity. The most recent support for this development exists through 
experiments that highlight significant discrepancies between maximal PDP enzyme 
activities and the intramuscular contents of PDP protein. This discrepancy has been 
observed in human skeletal muscle (Love et al., 2011) and various fiber type 
compositions (I, IIA & IIX/B) in rat hindlimb skeletal muscle (LeBlanc et al, 2007; 
LeBlanc et al., 2008). Furthermore, this phenomenon has been reported in response to 
multiple metabolic perturbations, such as aerobic exercise training (LeBlanc et al., 2008) 
and nutritional manipulation (LeBlanc et al., 2007). 
M.Sc. Thesis – J. R. Choptiany  Brock University 
 21 
From an investigatory perspective, these results have been documented within 
longitudinal (LeBlanc et al., 2007; LeBlanc et al., 2008) and cross–sectional study 
designs (Love et al., 2011). This consistency between experimental designs is significant, 
providing an integrated analysis that promotes the understanding of stable regulatory 
adaptations amongst the basal kinetics of PDP enzymes. The consistent documentation of 
this finding across methodologies has provided convincing validity towards this 
development. However, further investigation at the whole–tissue and cellular levels is 
required in order to identify the mechanisms underlying covalent modification of PDP. 
 Expression of both PDP isoforms (PDP1 & PDP2) is capable of being up– 
(LeBlanc et al., 2008) and down–regulated (LeBlanc et al., 2007), depending on 
metabolic perturbation. This plasticity is consistent with other catalytic subunits and 
proteins within the PDH complex (LeBlanc, Peters, Tunstall, Cameron–Smith, & 
Heigenhauser, 2004b; Maury et al., 1995). One study from LeBlanc et al. (2007) 
examined the regulatory potential of PDP enzymes in rat skeletal muscle in response to 
48 hours of starvation. In comparison to fed counterparts, significantly decreased PDP 
activity levels were observed within all major skeletal muscle fiber types of food–
deprived subjects (LeBlanc et al., 2007). Consequently, it was hypothesized that fat 
oxidation was part of the cellular efforts to conserve carbohydrate intermediates, which is 
a widely accepted response to nutritional states such as starvation and carbohydrate 
restriction (Sugden, Howard, Munday, & Holness, 1993). Furthermore, the change 
observed in PDP activity was reflected in a decreased flux through active PDH 
complexes in food–deprived rats (LeBlanc et al., 2007). It should also be noted that PDP 
activity measures are performed on mitochondrial extracts and are independent of 
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mitochondrial effectors. Therefore, PDP activity measures reflect stable changes that are 
a result of a given perturbation. However, when protein content of PDP isoforms was 
quantified between fed and food–deprived rats using Western blot analysis, no significant 
differences were reported with respect to PDP1 protein content. These findings suggest 
that the observed changes in PDP activity were not solely due to changes in PDP1. 
PDP1 is the ubiquitous isoform in skeletal muscle tissue (Huang et al., 1998), and 
its influence may be expected to dissipate in the context of nutritional perturbation. PDP1 
activity may indeed be reduced in response to starvation; however, this is not illustrated 
through measures of whole muscle protein content. PDP2 protein content was 
significantly reduced in red gastrocnemius muscles of food–deprived rats, but PDP2 
protein was entirely undetectable in soleus and white gastrocnemius muscles of all 
subjects (LeBlanc et al., 2007). A decreased PDP2 content is not surprising based upon 
this isoform’s sensitivity to insulin (Popp, Kiechle, Kotagal, & Jarett, 1980). In 
nutritional states where carbohydrate intake is dramatically reduced, intracellular 
signaling mechanisms that activate this isoenzyme may be silenced, effectively removing 
the driving force behind PDP2 transcription. This finding would have been significantly 
convincing if mirrored in PDP1, as well as in tissues that do not rely predominantly upon 
aerobic energy production through the PDH complex. However, the presence of PDP2 in 
skeletal muscle tissue has been nearly untraceable (Huang et al., 1998). Therefore, it 
cannot be accepted with confidence that a reduction in PDP activity in skeletal muscle is 
strictly due to decreased PDP2 isoform content (LeBlanc et al., 2007). 
A second study from LeBlanc et al. (2008) subjected lean and obese Zucker rats 
to 8 weeks of aerobic endurance training. Results demonstrated that 8 weeks of aerobic 
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training significantly increased PDP activity levels in all major fiber types of obese rats 
(LeBlanc et al., 2008). This finding was also observed in lean counterparts, but only in 
select oxidative muscles (soleus, 84% type I; red gastrocnemius, 30–51% type I)  
(LeBlanc et al., 2007) that rely upon aerobic energy production (LeBlanc et al., 2008). 
The training response in both subsamples indicates that an increased capacity to activate 
the PDH complex and oxidize carbohydrates is not limited to the treatment of nutritional 
challenges. However, as previously described, the protein content of individual PDP 
isoforms did not mirror patterns observed in enzyme activity. Increased PDP1 protein 
content reached statistical significance only in highly oxidative soleus muscles (LeBlanc 
et al., 2008). Significance was reached in red gastrocnemius muscles of obese rats, but 
was absent in lean counterparts; however, a smaller magnitude in adaptation is to be 
expected when working with lean subjects. Nonetheless, this detail may speak to a 
substantial physiological need with obesity and does not rule out the potential presence of 
PDP covalent regulation. With respect to PDP2 protein content, PDP2 was once again 
only detected in red gastrocnemius, and no significant differences were observed in 
response to aerobic endurance training (LeBlanc et al., 2008). 
In lieu of the physiological properties of PDP1, a cause and effect relationship 
between PDP activity and PDP1 expression cannot be made according to this 
investigation. With respect to PDP2, PDP1 is found in overwhelming quantities in 
skeletal muscle tissue (Huang et al., 1998), and its activity is almost entirely dependent 
upon the presence of intracellular calcium ions (Lawson et al., 1993). An enzyme of this 
nature would be expected to exhibit stable increases in skeletal muscle protein expression 
in response to an 8–week exercise training program with continuous allosteric activation. 
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The fact that this adaptation was not observed across all conditions and fiber types in 
concert with increased enzyme activity lends greater support to the notion that PDP 
enzymes may in fact be under the influence of an alternate level of regulation. It is 
reasonable to suggest covalent regulation as one potential alternate, as the 
phosphorylation of PDP would persist through the mitochondrial extraction procedure. 
Based upon the established regulatory adaptability of PDP activity, it is 
reasonable to suggest that relationships may exist between markers of metabolic fitness 
and PDP activity. Only one study has attempted to establish such correlations through the 
use of human skeletal muscle biopsies (Love et al., 2011). This study demonstrated that 
individuals with increased muscular aerobic capacity possessed a greater capacity for 
carbohydrate oxidation, as citrate synthase activity was significantly correlated with PDP 
activity (nmol  minute-1  mg mitochondrial protein-1) (Love et al., 2011). However, 
PDP1 protein content in whole muscle samples only accounted for 18% of the variance in 
PDP activity at the whole muscle level (Love et al., 2011). This finding illustrates that in 
a human sample characterized by significant variability in whole–body and muscular 
aerobic capacity, PDP1 protein content within whole tissue is not the sole determining 
factor of PDP activity, suggesting again that there is an alternative long–term regulatory 
mechanism for PDP activity. 
The covalent activation of PDP via phosphorylation has been previously 
demonstrated, but only in a cell culture model. Through the use of L6 myoblasts, it has 
been determined that the protein kinase C–delta (PKCδ) isoform undergoes rapid and 
transient translocation to mitochondria in response to insulin receptor activation (Caruso 
et al., 2001). Investigation of multiple kinase families, including various isoforms within 
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these families, showed that selective inhibition of PKCδ eliminates insulin–stimulated 
activity of the PDH complex. Inhibition of phosphatidylinositol–3–kinase and mitogen–
activated protein kinase families, as well as PKC–beta and PKC–epsilon isoforms caused 
no change in basal activities of the active PDH complex, indicating that these enzymes 
are uninvolved in the signaling cascade responsible for PDP phosphorylation (Caruso et 
al., 2001). 
PDP and PDK proteins act upon the E1α regulatory subunit of the PDH complex 
inside the mitochondria (Schnaitman & Greenawalt, 1968), and confirmation of PKCδ 
translocation to this region of the cell is crucial in establishing a direct physical 
relationship for this PKC isoform and PDP. Western blot analysis of basal [non–insulin– 
stimulated] cells has confirmed that PKCδ is primarily detected in the nuclear and 
cytosolic subcellular fractions (Caruso et al., 2001). However, insulin stimulation led to 
an increased presence of PKCδ in mitochondrial and plasma membrane fractions of L6 
myoblasts with reciprocal decreased content in the nucleus and cytosol. In addition to this 
subcellular redistribution, PKCδ activity was increased 2–fold within the mitochondria 
and plasma membrane in response to insulin stimulation (Caruso et al., 2001). Taken 
together, these data indicate that PKCδ responds directly to insulin–signaling and targets 
regulatory proteins of the PDH complex downstream. 
PDH complex activity levels are dependent upon concomitant changes to the 
combined regulatory activities of PDK and PDP enzymes (Linn, Pettit, & Reed, 1969). 
Through the use of a non–specific phosphatase inhibitor (sodium fluoride) and the 
suppression PKCδ protein expression, insulin activation of PDP activity was inhibited by 
95% in L6 myoblasts (Caruso et al., 2001). In comparison to basal controls, insulin 
M.Sc. Thesis – J. R. Choptiany  Brock University 
 26 
induced no effect on PDK activity whatsoever. The presence of a general kinase inhibitor 
(dichloroacetic acid) completely blocked PDK activity in both cell lines, and treatment 
with the same PKCδ antisense oligonucleotide caused no change in PDK activity levels 
(Caruso et al., 2001). These findings demonstrate that the insulin–stimulated activation 
and translocation of PKCδ targets only PDP specifically, as opposed to inactivating PDK. 
Furthermore, analysis of mitochondrial subfractions from L6 myoblasts demonstrated a 
radiolabeled 32P–phosphorylation of both PDP isoforms in response to PKCδ activation 
(Caruso et al., 2001). This experiment has established a physical protein–protein 
interaction in the form of phosphorylation upon PDP isoenzymes by PKCδ in cultured 
cells. However, there have been no studies to date to examine this regulation in a more 
physiological model. 
Based upon the fact that skeletal muscle is the major target of insulin action 
(Caruso et al., 2001), this signaling cascade presents a physiologically relevant 
explanation to current anomalies observed in studies of mammalian skeletal muscle PDP 
activity. Furthermore, it is must be understood that these L6 myoblasts expressed wild–
type human insulin receptors (Caruso et al., 2001). This methodological feature is 
significant with the respect to the extrapolation of these findings to PDH regulation in 
human skeletal muscle. However, these results have not yet been confirmed in intact 
skeletal muscle. More research is required in order to demonstrate these signaling 
mechanisms at the whole tissue level. 
Further support for an alternate intracellular signaling cascade leading to PDP 
phosphorylation has been suggested in response to AMP–activated protein kinase 
(AMPK) activation (Smith, Bruce, & Dyck, 2005). AMPK stimulation by 5–amino–4–
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imidazolecarbomoxide riboside significantly increased AMPK α2 isoform activity in 
soleus skeletal muscle strip incubations, promoting increased glucose uptake and fatty 
acid oxidation towards overall ATP production. Glucose oxidation was increased, 
potentially as a secondary response to an increase in glucose uptake, as demonstrated by 
significant increases in PDHa activity (Smith et al., 2005). However, increased flux 
through PDHa was observed with concurrent decreases in pyruvate concentrations, which 
is the primary working substrate for the basic PDH reaction (Smith et al., 2005). 
Consequently, these findings have generated further speculation that the PDH complex 
may be a direct downstream target of activated AMPK during times of decreased energy 
charge in skeletal muscle. 
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CHAPTER 2: 
Statement of the Problem 
Mammalian skeletal muscle has demonstrated responsive and adaptable PDP 
enzyme maximal activity through a variety of metabolic perturbations. However, these 
measurements of PDP maximal enzyme activity cannot be fully accounted for by changes 
in PDP skeletal muscle protein content. Sufficient evidence exists to implicate the 
covalent modification of predominant PDPs in mammalian skeletal muscle. Mirrored 
results between in vivo muscle tissues (human & rat) and cell culture lines confirm the 
regulatory potential of PDP enzymes. Collectively, these results demonstrate a 
discrepancy between PDP isoenzyme protein content and total PDP maximal enzyme 
activity. Therefore, this evidence confirms the need to further advance the understanding 
of PDP enzyme regulation by studying the phosphorylation state of PDP1 and PDP2 
isoenzymes. 
Purpose 
 The purposes of this thesis are: 1) to determine if there are differences in 
phosphorylation levels in PDP1 and PDP2 isoenzymes between basal and insulin–
stimulated conditions at the whole tissue level; and 2) to investigate whether 
mitochondrial enrichment of PKCδ is correlated with content of phosphorylated PDP1 
and PDP2 in intact skeletal muscle. 
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Hypotheses 
1) It is expected that phosphorylation levels of PDP isoforms will be increased in 
response to insulin stimulation compared to basal conditions. 
2) Total PDP and PDHa enzyme activity levels are expected to increase in response 
to insulin stimulation, and are expected to mirror any increases in PDP1 & PDP2 
phosphorylation (immunoprecipitation and Western blotting). 
3) Due to the fact that PKCδ has been shown to phosphorylate PDP isoforms, it is 
expected that increased mitochondrial enrichment of PKCδ will be observed in 
response to insulin stimulation. 
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CHAPTER 3: 
 
METHODS 
Study Design 
 This study implemented one treatment (insulin stimulation) with 80 match–paired 
rat extensor digitorum longus muscles from 40 male Long Evans rats. Phosphorylation of 
both PDP isoforms (PDP1 & PDP2) was determined at two sites: threonine (data not 
shown) and serine. Following surgical extraction, all muscles were incubated for a 30–
minute equilibration period in incubation medium (Medium199; Sigma–Aldrich, 
Oakville, Ontario, Canada). Muscles underwent incubation for a second 30 minute 
interval under basal (Medium199 only) or insulin–stimulated (Medium199 and 10 
mU/mL Humilin–R) conditions. Following the experimental incubation period, 44 
muscles were immediately frozen in liquid nitrogen and stored at –80° C for subsequent 
biochemical analysis. Frozen tissue was reserved for Western blotting of phospho–Akt 
protein content and for the determination of PDHa activity by radiolabeled 14C–acetyl–
CoA accumulation. Furthermore, frozen tissue was reserved for immunoprecipitation and 
Western blotting procedures in order to verify PDP phosphorylation. The remaining 36 
muscles were used fresh for the isolation of subsarcolemmal mitochondria. First, 
mitochondria were used for the analysis of PDP and CS activities. Analysis of PDP 
activity was expected to compliment any changes in PDP1 and PDP2 phosphorylation. 
Second, mitochondria were reserved for the analysis of mitochondrial PKCδ enrichment 
via Western blotting. PKCδ is believed to be the kinase responsible for phosphorylation 
of both PDP1 & PDP2 within the mitochondria (Caruso et al., 2001). Tyrosine residues 
were not investigated as a potential site of PDP phosphorylation, as the PKC family of 
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kinases targets serine and threonine residues only (Breitkreutz, Braiman–Wiksman, 
Daum, Denning, & Tennenbaum, 2007). 
Figure 2. Match–paired EDL tissue allocation by methodological procedure. 
*Five of eight match–paired muscles used in both procedures. 
Animals 
 Male (n = 40) Long Evans rats weighing an average of 110 ± 19 grams were 
obtained from Charles River Laboratories (Saint–Constant, Québec, Canada) at 3 weeks 
of age. All animals were housed in a controlled environment with a 12:12–h light–dark 
cycle, and were fed standard rat chow (23% protein, 11% fat, 67% carbohydrate; 5012 
Rat Diet, Lab Diet, Aberfoyle, Ontario, Canada) and water ad libitum. Animals were 
acclimatized to their new surroundings for 1 week before experiments commenced. All 
study protocols were approved by the Brock University Animal Care and Use Committee 
(ACUC). All procedures were consistent with the ethics of animal experimentation as set 
out by the Canadian Council on Animal Care (CCAC). 
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Surgeries 
 Animals were anaesthetized with an intraperitoneal injection of pentobarbital 
sodium (Euthanyl; Bimeda, Cambridge, Ontario, Canada) using a 27–gauge needle (60 
mg/1 kg body weight). Surgeries did not commence until the palpebral reflex and the toe 
pinch withdrawal response were absent. Bilateral extensor digitorum longus (EDL) 
muscles were extracted with defined and pre–sutured tendons intact (Gittings, 2009). At 
the conclusion of the dissection procedure, animals were euthanized humanely with an 
overdosed intraperitoneal injection of pentobarbital sodium (120 mg/kg body weight). 
Animals were monitored post–operatively until the cessation of cardiac activity was 
observed. 
Muscle Incubations 
Isolated muscle incubations were performed using a structurally intact skeletal 
muscle model. Immediately following extraction, longitudinal EDL muscles were placed 
in a controlled organ bath as quickly as possible (<5 s) in order to maintain tissue 
viability. Sutured muscles were fully submerged in a petri dish containing pre–warmed 
(25° C) and oxygenated (95% O2–5% CO2) Medium199 in preparation for the incubation 
apparatus. The petri dish was used in order to minimize tissue degradation variability 
between individual muscles, ensuring that all muscles were rapidly introduced to in vitro 
oxygenated conditions (Bonen, Clark, & Henriksen, 1994). Once distal sutures were 
hooked and secured in the petri dish, the muscles were inserted into a 15 mL incubation 
reservoir (Radnoti LLC, Monrovia, California, U.S.A.) containing pre–warmed and 
oxygenated Medium199. Proximal sutures were then suspended on force displacement 
transducer hooks (Grass Technologies, West Warwick, Rhode Island, U.S.A.). With both 
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sutures properly fixed within the incubation apparatus, the force transducer was adjusted 
to maintain 1 g of resting tension throughout the incubation period. Resting tension was 
applied in order to recreate an in vivo resting workload upon EDL muscles (Cermak, 
LeBlanc, Peters, Vandenboom, & Roy, 2009). All EDL muscles underwent an 
equilibration period (30 minutes) in order to return to baseline conditions after the rigors 
of surgical stress. For study of basal control muscles, equilibration incubations were 
maintained for a second 30–minute interval. For the incubation of contralateral insulin–
stimulated experimental muscles, Medium199 contained 10 mU/mL of human insulin 
(Humilin–R, Eli Lilly, Toronto, Ontario, Canada) (Collier, Bruce, Smith, Lopaschuk, & 
Dyck, 2006; Pehleman et al., 2005; Smith et al., 2007; Stefanyk et al., 2011). 
Experimental muscles were also incubated for an additional 30–minute interval. At the 
end of the incubation period, muscles were either immediately freeze–clamped in liquid 
nitrogen and stored at –80° C or processed fresh for the isolation of subsarcolemmal 
mitochondrial. 
 Previous research has illustrated that incubation conditions must be controlled 
properly to ensure that adequate diffusion of substrates and gases is permitted. 
Furthermore, conditions must be critically designed in order to maintain tissue viability 
and the biochemical integrity of metabolic pathways (Bonen et al., 1994). Young rats 
were obtained for all experiments in order to examine incubated EDL muscles of 
appropriate size and thickness. This selection was made with an aim to prevent 
oxygenation and diffusion limitations to all EDL muscle fibers. Rat EDL muscles were 
chosen over mouse EDL muscles as the most scientifically appropriate, as the mouse has 
a significantly higher metabolic rate than the rat (Bonen et al., 1994). This difference in 
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animal model is significant, as the use of the mouse model could lead to a greater 
consumption of oxygen by peripheral muscle fibers, therefore limiting oxygen supply to 
deeper fibers and producing anoxic conditions (Bonen et al., 1994). An incubation 
medium temperature of 25° C was selected in order to further promote the oxygenation of 
internal muscle fibers. All EDL muscles under study did not exceed a thickness of 2 mm 
(Cermak et al., 2009; Bonen et al., 1994), which is an appropriate diameter to ensure 
complete oxygenation of all fibers in an in vitro incubation medium warmed to 25° C 
(Hill, 1972). With respect to rats at 4 weeks of age and an average weight of 110.21 ± 
19.85 grams, the critical muscle thickness for adequate oxygenation of EDL muscles in 
vitro at 25° C is 1.94 mm (Segal & Faulkner, 1985). 
Mitochondrial Isolation 
 Intact subsarcolemmal mitochondria were isolated as originally described by 
Makinen and Lee (1968) and adjusted by Jackman and Willis (1996). Mitochondria were 
extracted from fresh extensor digitorum longus muscles following resting and insulin– 
stimulated incubations. Using an inverted petri dish placed on ice, fresh muscles were 
finely cut by hand using mincing scissors as quickly as possible. Approximately 5–15 mg 
of minced muscle was immediately frozen in liquid nitrogen and stored at –80° C for 
allocation to the citrate synthase activity assay (discussed later in the citrate synthase 
activity assay). 
 The remaining minced muscle was weighed and immediately placed in 500 µL of 
solution 1 (100 mM KCl, 40 mM Tris HCl, 10 mM Tris base, 5 mM MgSO4, 5 mM 
Na2EDTA, 1 mM ATP, 200 µM 7,8–dihydroxycoumarin (kinase inhibitor), and 1 
PhosSTOP tablet/10 mL (phosphatase inhibitor: Roche Applied Science, Laval, Québec, 
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Canada), pH 7.4). Muscles were further minced in solution 1 and transferred into a glass 
homogenizing potter and topped up with additional solution 1 in order to produce a 20–
fold dilute sample. All muscles were homogenized as gently as possible until an opaque 
homogenate was produced. Rigorous homogenization was avoided in order to maintain as 
many intact mitochondria as possible. Homogenates were then transferred to culture 
tubes in preparation for differential centrifugation. 
 Samples were first centrifuged at 700 x g for 10 minutes at 4° C in order to 
remove large cellular debris. Supernatants containing mitochondria were retained and 
transferred to clean eppendorf tubes. Supernatants were then centrifuged at 14,000 rpm 
for 10 minutes at 4° C in order to pellet mitochondria. Supernatants from this second spin 
were discarded. Mitochondria were resuspended in 10 volumes of solution 2 (100 mM 
KCl, 40 mM Tris HCl, 5 mM Tris base, 1 mM MgSO4, 100 µM Na2EDTA, 250 µM ATP, 
1% BSA, (w/v) 200 µM 7,8–dihydroxycoumarin, and 1 PhosSTOP tablet/10 mL, pH 7.4) 
in order to bind and remove all free fatty acids present in solution. Samples were then 
centrifuged at 7,000 rpm for 10 minutes at 4° C to recollect the mitochondria after 
washing. As a final washing step, mitochondria were resuspended in 10 volumes of 
solution 3 (100 mM KCl, 40 mM Tris HCl, 5 mM Tris base, 1 mM MgSO4, 100 µM 
Na2EDTA, 250 µM ATP, 200 µM 7,8–dihydroxycoumarin, and 1 PhosSTOP tablet, pH 
7.4) and once again centrifuged at 7,000 rpm for 10 minutes at 4° C. Following all 
washing steps, mitochondria were resuspended in a sucrose and mannitol buffer (220 mM 
sucrose, 70 mM mannitol, 10 mM Tris HCl, 100 µM Na2EDTA, 200 µM 7,8–
dihydroxycoumarin, and 1 PhosSTOP tablet/10 mL, pH 7.4) at a 1:1 w/v ratio (1 mg wet 
tissue weight/1 µL). A 5 µL aliquot of the mitochondrial suspension was added to 95 µL 
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of sucrose and mannitol to produce a mitochondrial total suspension (CSTS) for 
mitochondrial recovery analysis (discussed later in the citrate synthase activity assay). 
The remaining volumes of all mitochondrial extracts were reserved for use in the PDP 
activity assay. All products of the mitochondrial isolation procedure (whole tissue 
sections, mitochondrial extracts, and mitochondrial total suspensions) were stored at –80° 
C for future citrate synthase and PDP experiments. 
Immunoprecipitation 
 A piece of frozen EDL tissue (~20 mg) was homogenized on ice in 25 volumes of 
lysis buffer containing 50 mM Tris base (pH 7.4), 150 mM NaCl, 1 mM EGTA, 200 µM 
7,8–dihydroxycoumarin (Sigma–Aldrich, Oakville, Ontario, Canada), protease inhibitor 
cocktail (Roche Applied Science, Laval, Québec, Canada), and phosphatase inhibitor 
cocktail (Roche Applied Science, Laval, Québec, Canada). Each prepared homogenate 
was aliquoted into two portions, each containing 500 µg of protein. Volumes of whole 
homogenate containing 500 µg of protein were calculated according to protein 
determinations obtained through Bradford assay analysis. A 500 µL aliquot of lysis buffer 
was also prepared as a sample blank. Aliquots were incubated with polyclonal primary 
antibodies against serine or threonine phosphorylation residues (Millipore, Billerica, 
Massachusetts, U.S.A.) in order to bind all proteins in the phosphorylated state. 
Incubations with primary antibodies were carried out overnight at 4° C with gentle 
agitation (Elion, 2006). Immediately following the first round of incubations, all samples 
were loaded with 20 µL of protein G–PLUS agarose bead conjugate suspension (Santa 
Cruz Biotechnology, Dallas, Texas, U.S.A.) for a second overnight incubation at 4° C 
with gentle agitation (Elion, 2006). Samples were centrifuged at 13,000 rpm for 3 
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minutes and immunoprecipitated pellets were collected. All supernatants were discarded 
at this stage. Depending on the nature of the study, supernatants may have needed to be 
retained for Western blotting in order to ensure that all proteins of interest were cleared 
from the cell lysate and contained strictly within the immunoprecipitated pellet. Pellets 
were washed twice with 500 µL of 1x PBS and underwent centrifugation at 13,000 rpm 
for 1 minute following each wash. Aspirated supernatants from the washing phase were 
discarded. After the final wash, immunoprecipitated pellets and diluted whole 
homogenates (1 µg/µL) were resuspended in 2x electrophoresis sample buffer containing 
50 nM Tris–HCl (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, 5% (v/v) 2–
mercaptoethanol and 0.1% (w/v) bromophenol blue. All samples were solubilized in 
boiling water for 5 minutes before undergoing Western blot analysis. 
 Whole homogenates and blanks were included in the Western blot analysis for 
two significant reasons: 1) as a point of verification, as detection of PDP1 & PDP2 in 
whole homogenate ensured the proper technical execution of the analysis; and 2) as 
repeated samples within blots for the normalization of sample comparisons and analyses. 
Western Blot Analysis 
 Standard sodium dodecyl sulfate polyacrylamide gel electrophoresis was 
performed using 6% stacking and 14% separating gels. Proteins underwent migration for 
2 hours at 120 volts in running buffer containing 31 mM Tris–HCl (pH 8.3), 240 mM 
glycine, and 0.1% (w/v) SDS. Electrophoretically–separated proteins were transferred 
onto polyvinylidene fluoride (PVDF) membrane (Immobilon–P, Millipore, Billerica, 
Massachusetts, U.S.A.) for 1 hour at 100 volts. The transfer buffer contained 25 mM 
Tris–HCl (pH 8.3), 192 mM glycine, 20% (v/v) methanol, and 0.1% (w/v) SDS. 
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Membranes were incubated in Tris–buffered saline–Tween (TBST) buffer (pH 7.5) 
containing 20 mM Tris base, 137 mM NaCl, 0.1% (v/v) Tween–20, with 5% (w/v) non–
fat dry milk for 1 hour in order to block all non–specific binding sites. Membranes were 
then incubated overnight in 5% milk–TBST containing monoclonal primary antibodies 
against both PDP isoforms (PDP1 and 2; Kamiya Biomedical, Seattle, Washington, 
U.S.A.), monoclonal antibody against phospho–Akt (Cell Signaling Technology, Danvers, 
Massachusetts, U.S.A.), monoclonal primary antibody against PKCδ (Cell Signaling 
Technology, Danvers, Massachusetts, U.S.A.), or monoclonal primary antibody against 
CoxIV (Invitrogen Corporation, Grand Island, New York, U.S.A.). Membranes were 
washed 3 times with TBST, and incubated for 1 hour in 5% milk–TBST containing 
peroxidase–conjugated goat anti–mouse IgG or goat anti–rabbit secondary antibody 
(Sigma–Aldrich, Oakville, Ontario, Canada). Membranes underwent a second round of 
washing with TBST, and immunoprecipitated antibody–antigen complexes were 
visualized using a Fluorchem 5500 imaging station (Alpha Innotech, San Leandro, 
California, U.S.A.) after the addition of Luminata Forte chemiluminescent detection 
substrate (Millipore, Billerica, Massachusetts, U.S.A.). Blots were washed and total 
protein was stained with Ponceau S (Sigma–Aldrich, Oakville, Ontario, Canada), which 
was used to normalize sample loading between lanes on each blot. 
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Table 1. Protein specific ratios between primary antibodies and 5% blocking solution for 
Western blot development. 
 
Protein of 
Interest 
Molecular 
Weight (kDa) 
Primary 
Antibody 
Commercial 
Dilution 
Working Solution 
Pyruvate 
Dehydrogenase 
Phosphatase 
Isoform 1 
53 
Anti–Pyruvate 
Dehydrogenase 
Phosphatase 1 mAb 
(mouse IgG) 
1:3000 
3 µL 1°Ab in 9 mL 
blocking solution 
 
Pyruvate 
Dehydrogenase 
Phosphatase 
Isoform 2 
53 
Anti–Pyruvate 
Dehydrogenase 
Phosphatase 2 mAb 
(mouse IgG) 
 
1:3000 3 µL 1°Ab in 9 mL 
blocking solution 
 
Phospho–Akt 60 Anti–Phospho–Akt mAb (rabbit IgG) 1:1000 
7 µL 1°Ab in 7 mL 
blocking solution 
Protein Kinase 
C–Delta 78 
Anti–Protein Kinase 
C–Delta mAb (rabbit 
IgG) 
1:1000 7 µL 1°Ab in 7 mL blocking solution 
Cytochrome c 
Oxidase 
Subunit 4 
18 
Anti–Cytochrome c 
Oxidase Subunit 4 
mAb (mouse IgG) 
 
1:1000 7 µL 1°Ab in 7 mL 
blocking solution 
Serine 
phosphorylated 
proteins 
0–250 Anti–Phosphoserine pAb (rabbit IgG) 
 
1:500 14 µL 1°Ab in 7 mL 
blocking solution 
 
Table 2. Antibody specific ratios between secondary antibodies & 5% blocking solution 
for Western blot development. 
 
Primary 
Antibody 
Secondary 
Antibody 
Commercial 
Dilution 
Working 
Solution 
Anti–Pyruvate 
Dehydrogenase 
Phosphatase 1 mAb 
Horseradish Peroxidase 
Conjugated Goat 
Anti–Mouse 
1:5000 
2 µL 2°Ab in 10 mL 
blocking solution 
 
Anti–Pyruvate 
Dehydrogenase 
Phosphatase 2 mAb 
Horseradish Peroxidase 
Conjugated Goat 
Anti–Mouse 
1:5000 2 µL 2°Ab in 10 mL blocking solution 
Anti–Phospho–Akt 
mAb (rabbit IgG) 
Horseradish Peroxidase 
Conjugated Bovine 
Anti–Rabbit 
1:5000 2 µL 2°Ab in 10 mL blocking solution 
Anti–Protein Kinase 
C–Delta pAb (rabbit 
IgG) 
Horseradish Peroxidase 
Conjugated Bovine 
Anti–Rabbit 
1:5000 2 µL 2°Ab in 10 mL blocking solution 
Anti–Cytochrome c 
Oxidase Subunit 4 
(IgG) 
Horseradish Peroxidase 
Conjugated Goat 
Anti–Mouse 
1:5000 2 µL 2°Ab in 10 mL blocking solution 
Anti–Phosphoserine 
pAb 
Horseradish Peroxidase 
Conjugated Bovine 
Anti–Rabbit 
1:5000 2 µL 2°Ab in 10 mL blocking solution 
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Pyruvate Dehydrogenase Assay 
 Pyruvate dehydrogenase activity (active form; PDHa) was measured as previously 
described (LeBlanc et al., 2008; Putman et al., 1993), based upon the original methods of 
Constantin–Teodosiu, Cederblad, and Hultman (1991b). Working under liquid nitrogen, a 
piece of EDL tissue (10–20 mg) was chipped from the frozen whole muscle sample. The 
muscle fragment was added to a cooled homogenizing potter containing 200 µL of 
homogenizing buffer (pH 7.8; 200 mM sucrose, 50 mM KCl, 5 mM MgCl2, 5 mM EGTA, 
50 mM Tris HCl, 50 mM NaF, 5 mM DCA, and 0.1% (v/v) Triton X–100). Tissue was 
briefly homogenized by hand on ice to introduce PDK (DCA) and PDP (NaF) inhibitors 
immediately. Additional buffer was added in order to produce a 30–fold dilution, and 
samples underwent motor–driven homogenization at 400 rpm on ice until completion. 
 For each sample, the PDHa assay was run in triplicate; duplicate reactions were 
initiated with pyruvate and one assay blank was run with ddH2O. In order to determine 
the PDHa reaction rate, each sample was measured at 1, 2, and 3–minute intervals. 
Therefore, nine sub–samples result from each sample homogenate. In preparation for 
each sample’s assay, nine labeled culture tubes were loaded with 720 µL of PDHa 
reagent mix. The mixed solution was comprised of 75% (v/v) PDHa assay buffer (pH 
7.8) containing 144.4 mM Tris, 0.72 mM EDTA, and 1.44 mM MgCl2; 8.33% (v/v) 39 
mM NAD+; 8.33% (v/v) 13 mM CoA; and 8.33% (v/v) 13 mM TPP. Using a positive 
displacement pipette, 30 µL of homogenate was added to each tube. Culture tubes were 
then placed in a block heater and warmed to 37° C in preparation for optimal reaction 
conditions. 
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 Assay reactions were initiated by adding 30 µL of 26 mM pyruvate (ddH2O for 
blanks). Culture tubes were gently vortexed and immediately returned to the block heater. 
At this point in time, a stopwatch was started in order to monitor the tracking of reactions. 
At precisely 1, 2, and 3–minute intervals, 200 µL of active sample was transferred to 
labeled eppendorfs, which were pre–loaded with 40 µL of 0.5 M PCA in order to halt 
reactions. After acidifying at room temperature for 5 minutes, samples were neutralized 
with 10 µL of 1 M KHCO3. Neutralized samples were centrifuged at 10,000 x g for 3 
minutes at room temperature, and the resulting supernatant was reserved for the 
determination of acetyl–CoA content. 
Acetyl–CoA Assay 
 In order to determine acetyl–CoA concentrations for each sample, three reactions 
involving radiolabeled 14C–aspartate were conducted in order to tag endogenous acetyl–
CoA concentrations produced via PDH (Cederblad, Carlin, Constantin–Teodosiu, Harper, 
& Hultman, 1990). In a culture tube, radiolabeled 14C–oxaloacetate was first produced 
from a radiolabeled 14C–aspartic acid substrate via aspartate transaminase (AST). Via the 
AST enzyme, radiolabeled 14C–aspartate (amino acid) was deaminated in order to 
produce 14C–radiolabeled oxaloacetate (ketoacid). The liberated amine group was then 
transaminated to alpha–ketoglutarate (ketoacid) and glutamate (amino acid) was 
produced. 
14C–aspartate + alpha–ketoglutarate   AST   14C–oxaloacetate + glutamate 
 In separate culture tubes, radiolabeled 14C–oxaloacetate and exogenous citrate 
synthase (CS) were then introduced to all neutralized PDHa samples. Via the CS enzyme, 
acetyl functional groups (2–carbon) from endogenous acetyl–CoA and 14C–radiolabeled 
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oxaloacetate (4–carbon) were condensed in order to produce radiolabeled 14C–citrate (6–
carbon).  
14C–oxaloacetate + acetyl–CoA + H2O   CS   14C–citrate + CoASH 
This reaction was performed with a great enough concentration of radiolabeled 14C–
oxaloacetate in order to ensure that acetyl–CoA was the limiting reactant. 
 At this point in the assay, all endogenous acetyl–CoA was represented as 
radiolabeled 14C–citrate. However, samples contained radiolabeled 14C–citrate as well as 
leftover unreacted radiolabeled 14C–oxaloacetate. This presented a problem, as both 
compounds are negatively charged anions, and acetyl–CoA content is eventually 
determined by the quantification of radiolabeled 14C–anions. Therefore, all remaining 
radiolabeled 14C–oxaloacetate was reaminated via AST in order to reproduce radiolabeled 
14C–aspartate, which is a positively charged cation. 
14C–oxaloacetate + glutamate   AST   14C–aspartate + alpha–ketoglutarate 
This reaction was performed with a sufficiently high concentration of glutamate in order 
to ensure that any remaining radiolabeled 14C–oxaloacetate was the limiting reactant. 
 Using an ion exchange resin, positively charged compounds were separated from 
all samples. Resin–containing pellets were discarded, which left only radiolabeled 14C–
citrate in the supernatant solution. Following this purification, radiolabeled 14C–citrate 
(reflective of endogenous acetyl–CoA concentrations) was the only radiolabel remaining 
in each sample. All samples underwent scintillation counting in order to determine their 
respective radioactivity. Acetyl–CoA concentrations were determined based upon an 
acetyl–CoA standard curve. PDHa activities were then calculated based upon through 
linear regression based upon each sample’s radioactivity. 
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Citrate Synthase Assay 
 Citrate synthase activity was determined using samples collected via the 
mitochondrial isolation procedure in order to calculate mitochondrial recovery. The 
previously frozen piece of EDL tissue was homogenized on ice in 100 volumes of 
homogenizing buffer containing 100 mM KH2PO4 (pH 7.3) and 0.05% (w/v) BSA. Total 
mitochondrial suspension samples were retrieved from –80° C, as these samples were 
prepared in advance. All samples were frozen and thawed three times using liquid 
nitrogen in order to lyse mitochondrial membranes and release mitochondrial contents 
into solution. All CS assay reactions (whole homogenates and total mitochondrial 
suspensions) were performed in 250 µL blackened–sidewall microcuvettes. 
 Microcuvettes contained the following reagents: 150 µL of 100 mM Tris buffer 
(pH 8.3); 25 µL of 1 mM dithiobis–2–nitrobenzoic acid (DTNB) (pH 8.3); 40 µL of 3 
mM acetyl–CoA; 10 µL of 10% Triton–X; and 10 µL of sample (CSWH or CSTS). Once 
the microcuvette had been prepared, 15 µL of 10 mM oxaloacetic acid was added in order 
to initiate the citrate synthase reaction: 
Acetyl–CoA + Oxaloacetic acid   CS   Citrate + CoASH 
Upon the completion of the reaction, all liberated CoASH condensed with DTNB in order 
to produce DTNB–CoA. This secondary reaction caused a colour shift in the cuvette, 
with the original clear and translucent sample turning slightly yellow. 
 Using a spectrophotometer (Biochrom, Cambridge, England), sample absorbance 
was measured at 412 nm in 30–second intervals for a total of 5 minutes. Absorbance was 
tracked once the assay reaction was proceeding at maximal steady state (~30 seconds). 
Any change observed in sample absorbance at a given interval was dependent upon the 
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concentration of DTNB–CoA present in solution. Maximal citrate synthase activity was 
calculated on the basis of the molar absorption coefficient of DTNB at a wavelength of 
412 nm, and the dilution factor of the sample undergoing analysis (whole homogenate or 
total suspension). Please refer to Appendix 2 for a detailed summary of the citrate 
synthase calculations. Once CS activities were determined for all whole homogenates and 
total mitochondrial suspensions, mitochondrial recovery was calculated based upon the 
following calculation (Love et al., 2011, Srere, 1969): 
% Mitochondrial recovery = (CSTS ÷ CSWH)  100 
Pyruvate Dehydrogenase Phosphatase Assay 
 The PDP assay was performed on mitochondrial extracts. PDP activity was 
determined using a serine/threonine phosphatase assay system kit (Promega, Madison, 
Wisconsin, U. S. A.) and a custom synthetic PDH E1α phosphopeptide substrate (New 
England Peptide, Gardner, Massachusetts, U. S. A.). The assay was performed as 
previously described (LeBlanc et al., 2008; Love et al., 2011) with one adjustment that 
will be described later. 
 In preparation for the assay, mitochondrial suspensions were diluted to a final 
protein concentration of 2 µg/µL with sucrose and mannitol and a total volume of 50 µL. 
Samples were frozen and thawed three times using liquid nitrogen in order to lyse 
mitochondrial membranes in preparation for centrifugation. Samples were centrifuged at 
21,400 x g for 1 hour at 4° C in order to remove large cellular debris. Supernatants 
containing PDP protein of interest were retained, while pellets were discarded. 
 During the course of the 1–hour spin, a phosphate standard curve (0, 0.1, 0.2, 0.5, 
1, 2 nM inorganic phosphate) and phosphate–reducing spin columns were prepared. Ten 
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mL of ddH2O was passed through each spin column via gravity in order to moisten 
column filters. Spin columns were then loaded with 10 mL of Sephadex–G25 resin. Once 
the resin flowthrough drained by gravity, Sephadex beads were equilibrated with 10 mL 
of column storage buffer containing 10 mM Tris (pH 7.5), 1 mM EDTA, and 0.02% 
(w/v) sodium azide. Spin columns were centrifuged at 600 x g for 5 minutes at 4° C 
ensuring that all column storage buffer was collected. Mitochondrial supernatants were 
passed through spin columns via centrifugation at 600 x g for 5 minutes at 4° C in order 
to remove endogenous phosphate within in each sample. 
 Purified mitochondrial samples (5 µL) were added to a 96–well plate in addition 
to 11 µL of reaction buffer containing 250 mM imidazole (pH 7.2); 1 mM EGTA; 25 mM 
MgCl2; 0.1% (v/v) 2–mercaptoethanol; and 0.05% (w/v) BSA, as well as 21 µL of 
phosphate free water. The well plate was then incubated for 10 minutes at 37° C in order 
to equilibrate the samples for optimal reaction conditions. Previous studies conducted in 
our laboratory (LeBlanc et al., 2007; LeBlanc et al., 2008; Love et al., 2011) have 
implemented a general phosphatase inhibitor at this stage in the assay in order to isolate 
the function of the metal–dependent serine/threonine protein phosphatase (PPM) family, 
of which PDP is a member (Barford, 1996; Wera & Hemmings, 1995). However, unlike 
the preceding studies from our laboratory, an alternative phosphatase inhibitor cocktail 
(Roche Applied Science, Laval, Québec, Canada) was included in all solutions of the 
mitochondrial isolation procedure. The reasoning for this substitution is that the previous 
inhibitor was no longer commercially available for purchase. This alternative cocktail 
inhibitor targets the non–metal–dependent serine/threonine (PPP) phosphatase family, 
which is the only other classification of serine/threonine protein phosphatase. 
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Consequently, the traditional phosphatase inhibitor added during the assay itself was 
omitted. 
 The PDP reactions were initiated through the addition of 13 µL of 1.5 mM 
phosphopeptide substrate. The reaction proceeded for 30 minutes at 37° C, enabling 
endogenous PDP to dephosphorylate the synthetic PDH E1α phosphopeptide. Reactions 
were halted through the addition of 50 µL of molybdate dye to each well containing 
samples or phosphate standards. A 30–minute incubation at room temperature followed 
to allow for molybdate dye colour development. Standard curve and sample absorbance 
was measured at 600 nm in a microplate reader. 
 
Figure 3. Synthetic PDH E1α phosphopeptide amino acid sequence. 
Statistical Analysis 
 Data are reported as mean ± standard error of the mean (n = 8, n = 10 or n = 11 
per group as indicated). To enhance statistical power, one EDL muscle was used for the 
basal condition, and the second EDL muscle from the same animal was used for the 
insulin–stimulated condition. Match–paired samples were analyzed for significance using 
paired samples T–tests. Statistical significance was accepted at p < 0.05. 
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CHAPTER 4: 
RESULTS 
General Observations 
 
 Subject characteristics (n = 40) reveal two divergent subgroups with respect to 
animal weights (Table 1). In one grouping, similarly lighter weights were reported for 
those procedures that did not involve mitochondrial isolations (pAkt, PDHa, and 
immunoprecipitation analyses). In the second grouping, heavier weights were reported 
for the one procedure that required mitochondrial isolation (PKCδ). These similarities are 
expected, as all EDL tissue samples were collected from male Long Evans rats, aged 28 
days. Tissue sampling for the mitochondrial analyses required more time to perform, 
enabling some subjects within these lots of animals to grow heavier. 
 
M.Sc. Thesis – J. R. Choptiany  Brock University 
 48 
Phospho–Akt Protein 
 
 Western blotting was performed against pAkt, a major target of the insulin–
signaling cascade for glucose uptake, in order to verify a tissue response to insulin 
stimulation. Insulin stimulation of EDL tissue (Fig. 4, A and B) led to a 10–fold increase 
in pAkt protein content (p = 0.0002). 
 
 
 
Fig. 4. A: representative Western blot of phosphorylated Akt (pAkt, 60 kDa) protein in extensor 
digitorum longus skeletal muscle tissue incubated in basal and insulin–stimulated (10 mU/mL) 
media. The four lanes depict two matched–paired subjects. 30 µg of total skeletal muscle whole 
homogenate was loaded per lane. B: paired t–test comparison of pAkt protein content (arbitrary 
units) obtained from 8 matched–paired subjects. Values are expressed as means ± SEM. 
*Significant from basal counterpart, p < 0.05. 
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PDHa Activity 
 
 Insulin stimulation led to a 58% increase in PDHa activity expressed per kilogram 
of wet weight tissue compared to basal counterparts (Fig. 5), but failed to reach statistical 
significance (p = 0.057). 
 
 
 
Fig. 5. Paired t–test comparison of PDHa activity per kilogram of wet weight tissue in extensor 
digitorum longus (EDL) skeletal muscle tissue incubated in basal and insulin–stimulated (10 
mU/mL) media. Values are expressed as means ± SEM. 
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Immunoprecipitated Phospho–Serine PDP Protein 
 
 Insulin stimulation led to significantly increased immunoprecipitated serine–
phosphorylated protein for both PDP isoforms. PDP1 phosphorylation (Fig. 6, A and B) 
increased by 29% (p = 0.047), and PDP2 phosphorylation (Fig. 7, A and B) increased by 
48% (p = 0.006). Immunoprecipitation was also performed to test for the phosphorylation 
of threonine residues, which was not found amongst PDP isoforms (data not shown). 
 
 
 
Fig. 6. A: representative Western blot of immunoprecipitated serine–phosphorylated pyruvate 
dehydrogenase phosphatase 1 (pPDP1, 53 kDa) protein in extensor digitorum longus skeletal 
muscle tissue incubated in basal and insulin–stimulated (10 mU/mL) media. The eight lanes 
depict four matched–paired subjects. 10 µL of whole homogenate phosphoserine extract was 
loaded per lane. pPDP1 protein (arbitrary units) was normalized to total protein per lane via 
Ponceau S stain (arbitrary units). B: paired t–test comparison of phospho–PDP1 protein content 
obtained from eight matched–paired subjects. Values are expressed as means ± SEM. 
*Significant from basal counterpart, p < 0.05. 
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Fig. 7. A: representative Western blot of immunoprecipitated serine–phosphorylated pyruvate 
dehydrogenase phosphatase 2 (pPDP2 kDa) protein in extensor digitorum longus skeletal muscle 
tissue incubated in basal and insulin–stimulated (10 mU/mL) media. The eight lanes depict four 
matched–paired subjects. pPDP2 protein (arbitrary units) was normalized to total protein per lane 
via Ponceau S stain (arbitrary units). B: paired t–test comparison of phospho–PDP2 protein 
content obtained from eight matched–paired subjects. Values are expressed as means ± SEM. 
*Significant from basal counterpart, p < 0.05. 
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Mitochondrial PKCδ Protein 
 
 Mitochondrial subfractions were isolated in order to investigate potential 
enrichment of PKCδ in response to insulin stimulation. Mitochondrial PKCδ protein 
content (Fig. 8, A and B) increased by 45% (p = 0.0009). 
 
 
 
Fig. 8. A: representative Western blots of protein kinase C–delta (PKCδ, 78 kDa) and cytochrome 
c oxidase subunit 4 (CoxIV, 18 kDa) protein in mitochondrial subfractions from extensor 
digitorum longus skeletal muscle tissue incubated in basal and insulin–stimulated (10 mU/mL) 
media. The four lanes depict two matched–paired subjects. 3 µg of total mitochondrial protein 
was loaded per lane in both instances. PKCδ protein content (arbitrary units) was normalized to 
CoxIV protein content (arbitrary units). B: paired t–test comparison of mitochondrial PKCδ 
protein content obtained from eight matched–paired subjects. Values are expressed as means ± 
SEM. *Significant from basal counterpart, p < 0.05. 
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PDP and CS Activity 
 Pyruvate dehydrogenase phosphatase activity assay data is not shown. The PDP 
assay was unable to be completed based upon the preparation of mitochondria collected 
for the procedure. All four solutions used in the mitochondrial isolation procedure 
contained a general phosphatase inhibitor cocktail (Roche Applied Science, Laval, 
Québec, Canada), which appeared to have blocked PDP activity altogether. Additional 
pilot–testing of mitochondria that were extracted without inhibitors exhibited PDP 
activity, but those mitochondria extracted for PDP and CS analyses did not have activity. 
Inhibitors were included in the buffers in attempt to lock the phosphorylation state of 
each sample following whole tissue incubations, and to prevent cytosolic kinases and 
phosphatases from adding or removing phosphates during tissue homogenization 
procedures. Product information for the inhibitors clearly stated that the PPP family of 
protein phosphatases was targeted for inhibition, and not the PPM family of protein 
phosphatases (of which PDP is a member). However, specific phosphatase catalytic and 
regulatory domains respond to different forms of inhibition (Barford, 1996; Wera & 
Hemmings, 1995). Therefore, mitochondria were prepared under the assumption that the 
PDP enzymes would be unaffected. At the time of this decision, a great deal of 
importance was placed upon locking the phosphorylation state of the PDH enzyme 
complex as well as isolating the function of the PPM phosphatase. 
 Pilot testing using uninhibited mitochondrial samples yielded successful results in 
the PDP assay. However, not enough uninhibited samples remained in order to analyze a 
full data set of basal and insulin–stimulated samples. PDP assay data will be recollected 
at a later date using uninhibited samples to complete this study. 
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 Citrate synthase activity data, which would have been used to calculate 
mitochondrial recovery and muscle PDP activity, are reported in Appendix 3.  
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CHAPTER 5: 
 
DISCUSSION 
General Summary 
 This study is the first that we know of to examine the phosphorylation state of 
both PDP1 and PDP2 in response to insulin stimulation using intact skeletal muscle tissue. 
Furthermore, to the best of our knowledge, this is the first study to examine PDH 
complex activity by way of acetyl–CoA accumulation in response to insulin stimulation. 
The major findings of the present study are: 1) PDHa activity increased by 58% in 
response to insulin stimulation compared to basal counterparts (p = 0.057); 2) insulin 
stimulation led to increased phosphorylation of both PDP isoforms, with PDP1 and PDP2 
increasing by 29% (p = 0.047) and 48% (p = 0.006), respectively; and 3) mitochondrial 
protein content of PKCδ was enriched by 45% in response to insulin stimulation (p = 
0.0009). 
PDHa Activity 
 The present study demonstrated increased PDH complex in the active form in 
response to insulin stimulation (hypothesis 2). Although failing to reach statistical 
significance, the increased PDHa activity was trending strongly (p = 0.057). This finding 
supports previous research that implicates the PDH complex as a target of secondary 
messaging as part of the insulin–signaling cascade (Benelli et al., 1994; Caruso et al., 
2001; Huang, Wu, Bowker–Kinley, & Harris, 2002; Popp et al., 1980). To the best of the 
authors’ knowledge, this practice for PDHa activity measurement at the whole tissue 
level and in response to insulin stimulation has not been utilized in any previous literature. 
 One study has established increased PDHa activity in response to insulin 
stimulation, although within vastly different physiological contexts (Caruso et al., 2001). 
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The work of Caruso et al. (2001) implemented cell culture models, and reported a 2–fold 
increase in PDHa activity (measured via radioactive CO2 production from labeled 
pyruvate) in L6 myoblasts. This effect was observed at an insulin concentration of 100 
nM. The present study has extended these findings to more complex and less controllable 
physiological systems, coupled with a supra–physiological insulin stimulation of 10 
mU/mL, which corresponds to 71.74 nM (Heinemann, 2010). To contrast these 
stimulation criteria, plasma insulin concentrations peaked at ~75 µU/mL (~538 pM) in 
response to a high–carbohydrate meal following a 6 day high–fat diet in healthy subjects 
(Bigrigg, Heigenhauser, Inglis, LeBlanc, & Peters, 2009). At this point, it can only be 
speculated that such a potent stimulation was required to elicit this effect in PDHa 
activity, as the only studies to demonstrate these findings have done so outside 
physiologically relevant ranges. Separate from the work of Caruso et al. (2001), the 
insulin concentration used in the current study was selected in order to elicit maximal 
insulin–stimulated glucose transport into the cell, which was based upon research from 
one lab that performs similar whole tissue incubation experiments (Stefanyk et al., 2011). 
Further investigation may be required to narrow the physiological range of concentrations 
that elicit this response. 
 With respect to the PDHa method conducted within our laboratory, no 
documented precedent could be referenced to contrast the insulin–stimulated PDHa 
activities observed in this study. Two recent studies from our laboratory (LeBlanc et al., 
2007; LeBlanc et al., 2008) using an identical procedure reported similar resting PDHa 
activities as those seen in the current study. Basal EDL muscles had resting PDHa values 
ranging from 0.202–0.732 mmol  min–1  kg wet weight tissue (mean of 0.43; n = 11). 
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Other rat hindlimb tissues have demonstrated a similar range: 0.18–0.36 in soleus, 0.64–
0.85 in red gastrocnemius, and 0.31–0.41 nmol  min–1  g wet weight tissue in white 
gastrocnemius (LeBlanc et al., 2007; LeBlanc et al., 2008). Although fiber typing and 
carbohydrate oxidative potential undoubtedly varies across these muscles, a case can be 
made for general consistency in PDHa activity between resting rat skeletal muscle tissue. 
Consequently, the current resting PDHa values observed in EDL tissue can be accepted 
with the confidence that methodological procedures were performed successfully. Within 
this context, it would be expected that insulin stimulation would lead to increased activity 
levels, and therefore, the observation of a 58% increase in insulin–stimulated PDHa 
activity can be accepted as theoretically sound. 
 Pertaining to the insulin–stimulated PDHa values presented in this study, two 
physiological mechanisms are to be considered as potential explanations. First, insulin is 
a hormone that is impermeable to the cell membrane and dependent upon secondary 
messaging to elicit its effects (Pirola, Johnston, & van Obberghen, 2004). This 
recognition of hormone classification is of particular importance, as it provides support 
for any speculation of covalent modification upon PDH regulators. Second, increases in 
PDHa activity may simply be a consequence of increased glucose uptake and substrate 
provision in response to insulin stimulation. Increased glucose uptake could increase 
glycolytic flux and cytosolic pyruvate concentrations, which would inhibit PDK and 
contribute to increased PDHa activity. The incubating media used in all experiments 
(Medium199; Sigma–Aldrich, Ontario, Canada) contained a glucose concentration of 5.5 
mmol/L, which is within the normal range of fasting blood glucose levels. Increased 
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glucose uptake and catabolism could very well lead to an influx of metabolic 
intermediates that accelerate the basic PDH reaction (Peters, 2003). 
Immunoprecipitation and PDP Phosphorylation 
 Both PDP1 and PDP2 isoforms underwent increased phosphorylation in response 
to insulin stimulation (hypothesis 1). As with PDHa results from the current study, these 
findings are consistent with previous research in cell culture models (Caruso et al., 2001). 
Phosphorylation of the PDP1 isoform increased by 29% (p = 0.047) and PDP2 
phosphorylation increased by 48% (p = 0.006). Although these results have reached 
statistical significance, it is interesting to note that increased phosphorylation occurred to 
differing extents between both isoforms. 
 Prior to the commencement of this study, it was hypothesized that 
phosphorylation of PDP isoforms would increase in response to insulin stimulation. 
However, this hypothesis did not extend to any differences between isoforms with respect 
to any magnitude in response. Tissue distributions of PDP isoforms have revealed that 
PDP1 is highly expressed in rat skeletal muscle tissue, whereas PDP2 is overly expressed 
in rat liver (Huang et al., 1998). PDP1 is virtually undetectable in liver tissue and the 
same can be said for PDP2 in skeletal muscle; however, the specific muscle from which 
this analysis occurred was unspecified. From this perspective, one could argue that 
analysis of the PDP1 isoform will provide the greatest opportunity to observe a 
treatment’s effect in studies implementing skeletal muscle models. Consequently, the 
increase in PDP1 phosphorylation observed in the current study may be interpreted as 
somewhat surprising. 
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 PDP1 activity is largely dependent upon the presence of calcium ions (Huang et 
al., 1998), and PDP1 protein content is known to increase in response to aerobic training 
(LeBlanc et al., 2008). However, decreases in PDP2 protein content and activity induced 
by starvation and diabetes have exhibited recovery in response to treatment with insulin 
(Huang, Wu, Popov, & Harris, 2003). Therefore, from a regulatory perspective, one could 
argue that the analysis of the PDP2 isoform will provide the greatest opportunity to 
observe the effects of insulin stimulation, irrespective of tissue expression. Furthermore, 
in contrast to the findings from Huang et al. (1998), detection of PDP2 protein in rat EDL 
skeletal muscle tissue through Western blotting was not problematic. With all such 
factors taken into consideration, the stronger response observed in PDP2 phosphorylation 
is quite encouraging and consistent with previous literature from a theoretical perspective. 
 One limitation of our method to detect PDP phosphorylation is that sample 
loading between conditions during Western blotting was not based upon quantified 
protein determination after immunoprecipitation. Consequently, we cannot guarantee that 
basal and insulin–stimulated match–paired samples were studied under equal 
representation. Once the immunoprecipitation procedure had taken place, which requires 
the addition of protein IgG (anti–phosphoserine antibody and agarose beads) to skeletal 
muscle whole homogenates, we were unable to quantify sample protein content strictly 
representative of phosphorylated protein content. However, multiple steps were taken to 
control for this issue. First, protein determinations were quantified for each sample whole 
homogenate (µg/µL) prior to immunoprecipitation procedures. Second, using this data, 
sufficient primary antibody (40 µL) was applied in order to clear all serine–
phosphorylated proteins within a given quantity of prepared sample homogenate (500 µg). 
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This calculation is supported by product information from the antibody provider 
(AB1603, Anti–Phosphoserine Antibody; Billerica, MA, USA) and directed specifically 
towards the practice of immunoprecipitation techniques. Third, immunoprecipitation 
optimization procedures were pilot tested, which implemented an increasing gradient of 
anti–phospho–serine primary antibody (10, 20, 30 and 40 µL) as a method to ensure that 
all phosphorylated PDP protein was collected. Results from this pilot analysis revealed 
no change in phospho–PDP1 protein content following immunoprecipitation using 30 and 
40 µL of anti–phospho–serine primary antibody. As a result, these measures of control 
have provided assurance that all serine–phosphorylated proteins were harvested in both 
basal and insulin–stimulated samples in preparation for Western blotting of phospho–
PDP1 and phospho–PDP2. 
 Prior to electrophoresis, the samples were boiled in order to dissociate all protein–
antibody–agarose bead interactions. From this purified suspension, 10 µL from match–
paired samples were loaded for comparative Western blotting of phosphorylated PDP 
isoforms. As previously reported, all supernatants from immunoprecipitation experiments 
were discarded prior to Western blotting. In hindsight, this is now considered an 
oversight and limitation to the immunoprecipitation procedure. Western blotting 
immunoprecipitated supernatants against anti–phospho–serine primary antibody with 
negative results would have been demonstrated the clearance of all phosphorylated 
proteins. 
 A second limitation of our ability to detect PDP phosphorylation pertains to the 
ordering of antibodies applied towards immunoprecipitation and Western blotting. For all 
experiments involved in this study, immunoprecipitation was performed with a non–
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specific anti–phospho–serine primary antibody. Following immunoprecipitation, Western 
blotting was performed against PDP1 and PDP2 in order to quantify phosphorylation 
between basal and insulin–stimulated conditions. PDP is known to interact with other 
proteins that are serine–phosphorylated, and other protein interactions may potentially 
exist that have yet to be established. The possibility exists that the phosphorylation data 
presented in this study may not reflect changes in PDP phosphorylation in direct response 
to insulin stimulation compared to basal stimulation. In order to overcome this limitation, 
immunoprecipitation must be performed using anti–PDP1 and anti–PDP2 antibodies, 
following by Western blotting against serine–phosphorylated PDP within the 
immunoprecipitated pellet. 
 Results of the present PDP1 and PDP2 phosphorylation analyses suggest that the 
covalent modification of PDH regulating proteins underlies changes in PDHa activity in 
response to insulin stimulation. While this finding does not rule out the fact that increased 
glucose uptake in response to insulin stimulation occurred, these results support previous 
literature that PDPs are under their own system of regulatory control (Caruso et al., 2001). 
Furthermore, three recent studies from within this laboratory have all identified 
discrepancies pertaining to the relationship between PDP activity levels and 
intramuscular PDP protein content (LeBlanc et al., 2007; LeBlanc et al., 2008; Love et al., 
2011). These studies all suggested that an additional level of enzymatic control could 
account for the inconsistencies within their findings. The immunoprecipitation data from 
the present study confirmed that PDPs are capable of undergoing covalent modification, 
and suggest that PDP protein content and functional activity may not always correlate as 
a result. 
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Mitochondrial PKCδ Enrichment 
 Previous research has implicated PKCδ as the kinase responsible for PDP 
phosphorylation and upregulation (Caruso et al., 2001). Along with our PDP 
phosphorylation measures in whole tissue, these results suggest that a potential 
mechanism for PDP phosphorylation occurs in the mitochondria similar to what had 
previously been observed in cell culture (hypothesis 3). Our methodologies involved 
primarily subsarcolemmal mitochondrial isolations, which provided an opportunity to 
verify the mitochondrial enrichment of PKCδ and further substantiate established 
findings. Through Western blot analysis, it was observed that insulin stimulation led to a 
45% increased enrichment of mitochondrial PKCδ (p = 0.0009). PKCδ protein content 
was normalized to mitochondrial CoxIV protein content. CoxIV was selected as a 
mitochondrial housekeeping protein, as the content of this protein in mitochondria is not 
believed to change in response to insulin stimulation. 
 As a mitochondrial matrix–associated enzyme complex, it is not exactly known 
how PKCδ exerts phosphorylation upon PDP, or how it is able to enter the mitochondria 
per se. However, evidence does exist that highlights the capability for functional proteins 
to localize and permeate skeletal muscle mitochondria to facilitate metabolic processes. 
This has been observed in cytosolic lipid droplet proteins, which have been visualized 
inside the mitochondrial matrix space using electron microscopy (Bosma et al., 2011). 
Furthermore, Caruso et al. (2001) observed increased mitochondrial and decreased 
cytosolic contents of PKCδ in response to insulin stimulation in L6 myoblasts. Therefore, 
PKCδ may enter the mitochondrial matrix in order to come into physical contact with 
regulatory subunits of the PDH complex. 
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Future Directions 
 Results from the current study can be applied towards further investigation. First, 
although immunoprecipitation data from this study has suggested that PDP1 and PDP2 
are capable of undergoing serine phosphorylation, this methodology should be refined in 
order to confirm the current findings. In order to clearly demonstrate that PDP isoforms 
undergo increased phosphorylation in response to insulin stimulation, 
immunoprecipitation must be performed against PDP1 and PDP2 isoforms in separate 
experiments. Following immunoprecipitation, Western blotting of harvested PDP pellets 
against anti–phospho–serine primary antibody may confirm changes in phosphorylation 
for each PDP isoform respectively. On another note however, limitations of the current 
phosphorylation data perhaps provide justification for the production of anti–phospho–
PDP1 and anti–phospho–PDP2 primary antibodies in order to advance these findings. 
 Second, it has only been speculated that the covalent modification of PDP 
isoforms will result in PDP activation, accompanied by increased PDP activity. 
Methodological issues pertaining to the PDP assay have been established, as previously 
stated. Additional work is required to overcome these current issues, namely by selecting 
an ideal phosphatase inhibitor in order to isolate the specific activity of PDH 
phosphatases. The addition of PDP activity assay data would greatly enhance the existing 
data of current study, and would allow for more robust conclusions with respect to a 
potential signaling cascade between insulin stimulation and regulators of the PDH 
complex. 
 Third, results from this study can be applied towards further research involving 
the contractile stimulation of intact skeletal muscle tissue. Physical activity is a major 
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mechanism leading to increased PDH activity (Howlett et al., 1998), yet the covalent 
activation of PDP protein has yet to be established in response to this perturbation. 
Current equipment within the Centre for Bone and Muscle Health can allow for this study 
to be reproduced using an in vitro incubation model with contractile stimulation. Previous 
research has suggested a potential signaling cascade between AMPK and PDH, 
irrespective of increased substrate provision to the PDH complex (Smith et al., 2005). 
However, limitations surrounding immunoprecipitation and PDP activity assay 
procedures will also have to be addressed in order to investigate this question. 
Summary and Perspectives 
 This study is the first that we know of to examine changes in activity of the PDH 
complex in response to insulin stimulation using intact skeletal muscle tissue. 
Furthermore, this study also confirms previous findings conducted in cell culture by 
Caruso et al. (2001) that 1) with indirect evidence, both PDP1 and PDP2 are subject to 
covalent regulation at their serine residues, with increased phosphorylation observed in 
response to insulin stimulation; and 2) PKCδ is enriched in subsarcolemmal mitochondria 
serving as the potential kinase responsible for the phosphorylation of PDP in response to 
insulin stimulation. Taken together, this is the first study that we know of to demonstrate 
these findings at the whole tissue level with greater physiological relevance in 
comparison to work in cell culture models. Furthermore, these data extend studies 
previously conducted in our laboratory (LeBlanc et al., 2007; LeBlanc et al., 2008; Love 
et al., 2011). Each of these studies demonstrated analytical discrepancies between 
intramuscular PDP protein content and PDP activity. All three studies speculated a novel 
form of regulation upon PDP isoforms at the whole tissue level, and results of the current 
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study suggest that covalent modification of PDP may have contributed to previous 
findings. 
 It has long been reported that insulin is an activator of the PDH complex, based 
upon its ability to reverse the effects of PDH activity suppression via increased PDK 
protein expression in response to diabetic perturbations (Wu et al., 1998; Wu, Inskeep, 
Bowker–Kinley, Popov, & Harris, 1999). The current study suggests the presence of a 
signaling cascade between insulin receptor activation and the PDH complex via covalent 
regulation of PDP. However, without PDP activity data to support the PDP 
phosphorylation data presented in this study (hypothesis 2), an established sequence of 
signaling events cannot be confirmed between mitochondrial PKCδ enrichment, covalent 
activation of PDP, and increased PDHa activity.  
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Appendix 1: Laboratory Procedures 
 
Appendix 1a. Skeletal Muscle Tissue Surgical Extraction: Extensor Digitorum Longus 
 
Materials & Apparatus 
 
• Pentobarbital sodium 
• Saline 
• Absorbent gauze 
• Absorbent surgery pad 
• Non–absorbable surgical suture 
• Surgical tools 
- 1 pair operating scissors 
- 1 pair tissue forceps 
- 1 pair straight thin tip forceps 
- 1 pair curved thin tip forceps 
- 1 scalpel handle 
- 1 surgical blade 
• Tissue culture media (Medium 199) 
 Refer to Appendix 3: Components of Medium 199 
• 1 mL syringe 
• 27–gauge X 1¼ inch needle 
 
Reagents 
 
1. Saline Diluted Pentobarbital Sodium 
 
o 73% (v/v) Saline 
o 27% (v/v) Pentobarbital sodium 
- Store at room temperature in a locked cabinet 
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Protocol 
Surgical Preparation 
1. Lead the rat into a cylinder toy, and retrieve from its cage by the base of the tail. 
2. Place the rat onto the surgery pad and gently position the animal for 
intraperitoneal injection. 
(Hint: the use of a cylinder toy as an anesthetic aid enables the surgeon to handle 
the rat in a comfortable manner. Through repeated observation, this technique 
significantly reduces the amount of stress placed upon the animal when moving 
from the rat’s cage to the lab bench. This device enables easier location of the 
injection site, and the application of an accurate needle stick, without placing 
force directly upon the animal.) 
3. Administer an introductory dose of anesthetic and return the rat to its cage. 
4. Allow sufficient time for the animal to rest and fall under anesthesia. 
5. Continually test palpebral and toe–pinch reflexes. Do not begin the surgical 
procedure until these reflexes are entirely withdrawn. 
6. Top up the rat with additional injections if necessary in order to achieve the 
appropriate level of anesthesia. 
7. Record the weight of the animal during this prepatory period. 
Surgical Extraction 
8. Begin surgery by cutting around the ankle joint with operating scissors, directly 
distal to the hindlimb fur line. 
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9. Using operating scissors, cut proximally along the medial line of the hindlimb. 
(Hint: this cut allows for gentle retraction of the hindlimb epidermis with minimal 
force, significantly reducing the amount of stress placed upon the hindlimb.) 
10. Retract the epidermis in order to expose the entire hindlimb. 
11. Perform blunt dissection on the epidermis of the anterior foot in order to expose 
tendons of the superficial distal anterior hindlimb musculature. 
12. Locate and isolate the distal tibialis anterior (TA) tendon, and make small 
incisions on either side with a scalpel. 
13. Using forceps (pattern 5), raise the distal TA tendon in order to fully isolate this 
tendon from other hindlimb musculature. 
14. Cut the distal TA tendon. 
15. Dissect through the medial fascia covering TA, cutting proximally towards the 
knee joint with direct pressure against the tibia. 
(Hint: ensure that this cut is superficial as the sole purpose is to penetrate the 
fascia; a deep incision will damage the extensor digitorum longus (EDL) muscle.) 
16. Using forceps (pattern 7), pinch the distal belly of the TA muscle and retract until 
this tissue is solely anchored at the proximal attachment. 
17. Grasp TA at the proximal attachment and remove this tissue. 
(Hint: a poor dissection can leave plenty of frayed muscle and connective tissue. 
In order to obtain a clean dissection, grasp TA as close to the proximal attachment 
as possible and slowly retract with force until the tissue separates naturally. This 
technique will result in a clean kneecap with a clear view of the EDL muscle.) 
18. Using forceps (pattern 7), slide the curved tips of this tool underneath EDL. 
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19. Gently glide along the length of the muscle in order to dissect free from 
connective tissue, and to obtain a cleaner view of both tendons. 
20. Remove as much connective tissue at the ankle joint as possible in order to fully 
expose the distal EDL tendon. 
21. Fasten one suture with a double knot around the distal tendon. 
(Hint: it is crucial to tie the knots of this suture as close to the muscle as possible, 
in order to obtain ideal installation conditions within the incubation reservoir.) 
22. Using a scalpel, perform fine dissection upon the lateral musculature above the 
knee joint in order to fully expose the proximal EDL tendon. 
(Hint: deep or careless dissection can damage the proximal EDL tendon. It is 
imperative to gently cut through the vastus musculature leaving this tendon 
intact.) 
23. Using forceps (pattern 7), glide underneath EDL at the knee joint with force in 
order to detach the proximal tendon from the kneecap. 
24. Fasten the second suture with a double knot around the proximal tendon. 
(Hint: the knots of this suture do not need to be tied against the tissue, as 
additional length to the second suture will allow for a quick and easy installation 
into the incubation reservoir.) 
25. Cut both EDL tendons and proceed to suspension within the incubation reservoir. 
References 
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Figure A1.1. Extensor Digitorum Longus amongst the rat hindlimb musculature. 
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Appendix 1b. Isolation of Skeletal Muscle Tissue Subsarcolemmal Mitochondria 
 
Materials & Apparatus 
 
• Adenosine triphosphate (ATP) 
• Bovine serum albumin (BSA) 
• Disodium ethylenediaminetetraacetic acid (Na2EDTA) 
• Kinase inhibitor (7,8–dihydroxycoumarin) 
• Magnesium Sulfate (MgSO4) 
• Mannitol 
• Phosphatase inhibitor cocktail 
• Potassium chloride (KCl) 
• Sucrose 
• Tris base 
• Tris hydrochloride (Tris HCl) 
• Glass tissue grinders 
• Mincing scissors 
• Petri dish 
 
Reagents 
 
1. Chappell–Perry Solution 1 – pH 7.4 
 
o 100 mM KCl 
o 40 mM Tris HCl 
o 10 mM Tris base 
o 5 mM MgSO4 
o 5 mM Na2EDTA 
o 1 mM ATP 
o ddH2O (500 mL final volume) 
- Store at 4° C 
 
2. Chappell–Perry Solution 2 – pH 7.4 
 
o 100 mM KCl 
o 40 mM Tris HCl 
o 5 mM Tris base 
o 1 mM MgSO4 
o 100 µM Na2EDTA 
o 250 µM ATP 
o 1% BSA 
o ddH2O (500 mL final volume) 
- Store at 4° C 
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3. Chappell–Perry Solution 3 – pH 7.4 
 
o 100 mM KCl 
o 40 mM Tris HCl 
o 5 mM Tris base 
o 1 mM MgSO4 
o 100 µM Na2EDTA 
o 250 µM ATP 
o ddH2O (500 mL final volume) 
- Store at 4° C 
 
4. Sucrose & Mannitol – pH 7.4 
 
o 220 mM Sucrose 
o 70 mM Mannitol 
o 10 mM Tris HCl 
o 100 µM Na2EDTA 
o ddH2O (500 mL final volume) 
- Store at 4° C 
 
 Per 10 mL of Solutions 1, 2, 3, and Sucrose & Mannitol 
 
o 200 µM 7,8–dihydroxycoumarin 
o 1 PhosSTOP tablet 
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Protocol 
Tissue Preparation 
1. Prior to any handling of fresh tissue, gather the following materials and 
immediately place them on ice: one petri dish, glass tissue grinders, one 
eppendorf tube, one glass culture tube, and a working volume of solution 1. 
(Hint: label the eppendorf and culture tubes for the sample to be processed. 
Ensure that the homogenizing plunger is placed within the homogenizing potter to 
avoid any water contamination. Place the petri dish upside down, and depress it to 
ensure that the underside is in direct contact with ice.) 
2. Add a base volume of solution 1 to the labeled eppendorf tube (Example: 500 µL). 
3. Place freshly collected EDL tissue onto the petri dish and roughly mince. 
(Hint: ensure that any fresh tissue is on ice at all times in order to maintain tissue 
viability.) 
4. Isolate a small chunk (~5–10 mg) of minced tissue and immediately snap–freeze 
it in liquid nitrogen. 
5. Transfer the chunk to a labeled eppendorf tube. Keep this tissue in liquid nitrogen 
until it can be transferred to –80° C storage. 
(Hint: this chunk will be reserved for use in the citrate synthase assay for the 
measurement of mitochondrial recovery). 
6. Working as quickly as possible, transfer the remaining minced tissue to a weigh 
scale and record its weight in milligrams (Example: 40 mg). 
(Hint: this step must be done as quickly as possible as the tissue sample will be 
taken off ice, and tissue viability could potentially be compromised). 
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7. Once the tissue has been weighed, immediately transfer it to the labeled eppendorf 
containing solution 1. Keep this eppendorf tube on ice. 
8. Continue to mince the tissue in the eppendorf until only tiny chunks remain 
suspended. 
9. Calculate the remaining volume of solution 1 required in order to produce a 20–
fold dilute homogenate (Example: 40 mg of tissue within 800 µL of solution 1). 
10. Cut off the end of a 1 mL pipette tip and transfer the minced tissue into the 
homogenizing potter. 
(Hint: when pipetting the minced tissue into the homogenizing potter, pre–cutting 
the tip will decrease the likelihood that any tissue will remain left behind in the 
pipette tip). 
11. Once the tissue has been transferred, place the potter back on ice and add the 
remaining volume of solution 1 (Example: 300 µL). 
12. Gently homogenize the tissue on ice at all times for a minimum of 30 plunges, or 
until a pink opaque homogenate is produced. 
(Hint: homogenizations for mitochondrial isolation must be performed as gently 
and patiently as possible in order to preserve intact mitochondria). 
13. Once fully homogenized, rinse the inner walls of the potter with the homogenized 
tissue to collect any mitochondria that may have clung to the sides of the potter. 
14. Transfer the homogenate to the labeled culture tube. 
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Mitochondrial Isolation 
 
15. Spin #1: swinging bucket rotor, 4° C, 10 minutes, 700 x g. 
(Hint: the purpose of spin #1 is to pellet out all bulky cellular debris). 
16. Retain the supernatant, which contains the mitochondria, and discard the pellet. 
17. Transfer the supernatant to a clean and labeled eppendorf tube. 
18. Spin #2: small rotor, 4° C, 10 minutes, 14,000 rpm. 
19. Retain the pellet, which contains the mitochondria, and discard the supernatant. 
20. Resuspend the mitochondrial pellet in 10 volumes of solution 2 (Example: 400 
µL). 
21. Spin #3: small rotor, 4° C, 10 minutes, 7,000 rpm. 
(Hint: the purpose of spin #3 is the first cleaning step. Solution 2 contains BSA, 
which will bind all free fatty acids within the sample.) 
22. Retain the mitochondrial pellet and discard the supernatant. 
23. Resuspend the mitochondrial pellet in 10 volumes of solution 3. 
24. Spin #4: small rotor, 4° C, 10 minutes, 7,000 rpm. 
(Hint: the purpose of spin #4 is the second cleaning step. Solution 3 is very 
similar in contents to solution 1, and will wash the resuspended mitochondria). 
25. Retain the clean mitochondrial pellet and discard the supernatant. 
26. Resuspend the mitochondrial pellet in sucrose & mannitol at a 1:1 w/v ratio 
(Example: 40 µL). 
27. Transfer 5 µL of the mitochondrial extract into a labeled eppendorf containing 95 
µL of sucrose & mannitol to produce a 20–fold dilute total mitochondrial 
suspension. 
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(Hint: this suspension will be reserved for use in the citrate synthase assay for the 
measurement of mitochondrial recovery). 
28. Immediately snap–freeze the mitochondrial extract and total suspension in liquid 
nitrogen. 
29. The subsarcolemmal mitochondrial isolation is now complete. Three subsamples 
should result for every fresh tissue sample that is processed: 1) whole muscle 
tissue chunk; 2) mitochondrial extract; and 3) total mitochondrial suspension.  
Store all samples at –80° C for future use. 
References 
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Appendix 1c. Homogenization of Whole Skeletal Muscle Tissue 
 
Materials & Apparatus 
 
• Ethylene glycol tetraacetic acid (EGTA) 
• Kinase inhibitor (7,8–dihydroxycoumarin) 
• Phosphatase inhibitor cocktail 
• Protease inhibitor cocktail 
• Sodium chloride (NaCl) 
• Tris–hydrochloride (Tris HCl) 
• Glass tissue grinders 
 
Reagents 
 
1. Lysis Buffer – pH 6.8 
 
o 150 mM NaCl 
o 50 mM Tris HCl 
o 1 mM EGTA 
o ddH2O (1 L final volume) 
- Store at 4° C 
 
 Per 10 mL Lysis Buffer 
 
o 200 µM 7,8–dihydroxycoumarin 
o 1 cOmplete ULTRA EDTA–free tablet 
o 1 PhosSTOP tablet 
- Make fresh before use 
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Protocol 
 
1. Gather tissue grinders and lysis buffer from storage and place these materials on 
ice. Allow sufficient time for cooling before processing any tissue samples. 
(Hint: keep the homogenizing pestle inside the potter to avoid water 
contamination within the homogenization apparatus.)  
2. Retrieve EDL tissue samples from –80° C storage and immediately place in liquid 
nitrogen prior to handling. 
3. Using a foam stand for support, place a base volume of lysis buffer into the 
homogenizing potter (Example: 200 µL). 
4. Place the potter onto a weigh scale and tare the scale. 
5. Using tweezers, drop the frozen wet tissue into the potter. Allow for the scale to 
settle and record the weight of the tissue. 
(Hint: frozen tissue should be placed in cold buffer upon removal from liquid 
nitrogen in order to maintain tissue viability.) 
6. Calculate the remaining volume of lysis buffer required in order to produce a 25–
fold dilute homogenate (Example: 40 mg of skeletal muscle tissue within 1 mL of 
lysis buffer). 
7. Place the potter on ice, and add the remaining lysis buffer (Example: 800 µL). 
8. Homogenize the tissue on ice at all times for a minimum of 30 plunges, or until a 
pink opaque homogenate is produced. 
(Hint: when held up to light, with the pestle fully depressed into the potter, large 
connective debris should be the only visible material left unprocessed.) 
9. Store whole homogenate in a labeled eppendorf tube at –80° C. 
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Appendix 1d. Quantitative Determination of Proteins: The Bradford Method 
 
Materials & Apparatus 
 
• Bovine serum albumin (BSA) 
• Protein assay dye reagent concentrate 
• Microplate reader 
• Skirted microtiter 96–well plate 
 
Reagents 
 
1. Stock BSA Solution (1 mg/mL) 
 
o 100 g bovine serum albumin 
o ddH2O (100 mL final volume) 
- Aliquot into eppendorf tubes for individual trials 
- Store aliquots at –20° C and thaw before use 
 
2. Stock Protein Assay Dye Reagent (1:4 dilution) 
 
o 20% (v/v) concentrated colorimetric assay dye 
o 80% (v/v) ddH2O 
- Store at 4° C 
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Protocol 
Standard Curve Preparation 
1. Retrieve all tissue samples from –80° C storage and place on ice. 
2. Remove one aliquot of 1 mg/mL stock BSA solution from storage. Let thaw and 
immediately place on ice. 
3. Prepare all BSA standard solutions and store in labeled eppendorf tubes on ice. 
Table A1.1. Volumes of Stock BSA and ddH2O required for the preparation of the 
Bradford protein assay standard solutions. 
 
Protein Concentration 
(mg/mL) 
Stock BSA Solution 
(µL) 
ddH2O 
(µL) 
1 1000 0 
0.5 500 (from 1 mg/mL) 500 
0.25 500 (from 0.5 mg/mL) 500 
0.125 500 (from 0.25 mg/mL) 500 
0.05 100 (from 0.5 mg/mL) 900 
0 0 1000 
 
Sample Preparation 
4. Prepare labeled eppendorf tubes for all samples to be analyzed for protein 
quantification. 
5. Prepare 10–fold dilutions for all samples by loading individual eppendorf tubes 
with 10 µL of whole homogenate and 90 µL of ddH2O. 
(Hint: when working with mitochondrial samples, 20–fold dilutions are required). 
6. Return whole homogenates to –80° C storage, and keep diluted samples on ice. 
Bradford Protein Assay 
7. Retrieve a clean 96–well plate. If using an old plate, wash it thoroughly in order to 
ensure that the plate is free of any remnants from previous use. 
(Hint: the Bradford method is a sensitive spectrophotometric procedure that is 
fully dependent upon samples’ color development and subsequent light absorption. 
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Colour presents as a result of a reaction between the protein assay dye reagent and 
the positively charged amine groups of proteins within a sample. Consequently, 
any debris on the well plate could interfere with absorption readings.)  
8. Pipette 10 µL of each prepared standard solution and diluted sample into the 96–
well plate in triplicate. 
9. Pipette 200 µL of stock protein assay dye reagent into each well. 
(Hint: use of a multi–channel pipette will save time at this step. However, 
individually loading each well with a single channel pipette will lead to greater 
consistency, accuracy and superior results.) 
10. Allow a minimum of 2 minutes to pass for proper colour development to occur 
(Figure A1.2). 
11. Insert the well plate into the microplate reader to generate absorbance readings. 
12. Open KC4™ data analysis software, and ensure that the reading parameters are 
set to absorbance. 
13. Define the reading parameters by the following details: absorbance wavelength of 
595 nanometers, shaking intensity level of 3 and shaking duration of 5 seconds 
(Figure A1.3). 
14. Proceed to read the absorbance of each standard and sample (Figure A1.4). 
15. Copy the absorbance readings into a Microsoft® Excel spreadsheet, and generate 
a standard curve by plotting known protein concentrations (BSA standard 
solutions) against their average absorbance readings. 
 
M.Sc. Thesis – J. R. Choptiany  Brock University 
 95 
16. Outfit the standard curve with a polynomial trendline, and display the quadratic 
equation derived from this curve (Figure A1.5). 
(Hint: set BSA standards along the Y–axis and mean absorbance readings along 
the X–axis. With this setup, one can apply the absorbance readings as the 
unknown ‘X’ and solve for ‘Y’ (sample protein concentration) using this 
quadratic equation.) 
17. Subtract the average absorbance reading of water for every sample, and calculate 
the unknown protein concentrations for all samples using the quadratic equation. 
(Hint: ensure that all protein concentrations are multiplied by their dilution factor 
in order to obtain true quantifications, as sample homogenates were diluted 10–
fold with ddH2O.) 
References 
1. Bradford, M. M. (1976). A rapid and sensitive method for the quantification of 
 microgram quantities of protein utilizing the principle of protein–dye 
 binding. Analytical Biochemistry, 72, 248–254. 
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Figure A1.2. 96–well plate with BSA standards loaded in triplicate. 
 
 
Figure A1.3. Reading parameters in preparation for absorbance quantification. 
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Figure A1.4. Absorbance readings for 96 wells with standard values highlighted. 
 
Figure A1.5. Scatterplot displaying known protein concentrations the against mean 
absorbance readings. 
M.Sc. Thesis – J. R. Choptiany  Brock University 
 98 
Appendix 1e. Immunoprecipitation of Serine–Phosphorylated Proteins 
 
Materials & Apparatus 
 
• Anti–phosphoserine primary antibody 
• Bromophenol blue 
• Disodium hydrogen phosphate (Na2HPO4) 
• Glycerol 
• 2–mercaptoethanol 
• Potassium chloride (KCl) 
• Potassium dihydrogen phosphate (KH2PO4) 
• Protein G PLUS–Agarose conjugate bead suspension 
• Sodium chloride (NaCl) 
• Sodium dodecyl sulfate (SDS) 
• Tris base 
• 1 mL syringe 
 
Reagents 
 
1. 10x Stock Phosphate Buffered Saline (PBS) – pH 7.4 
 
o 1.37 M NaCl 
o 30 mM KCl 
o 80 mM Na2HPO4 
o 30 mM KH2PO4 
o ddH2O (100 mL final volume) 
- Store at 4° C 
- Dilute to 1x PBS as needed 
 
2. 2x Sample Buffer – pH 6.8 
 
o 25% (v/v) 1 M Tris base 
o 10% (v/v) glycerol 
o 20% (v/v) 10% SDS 
o 5% (v/v) 2–mercaptoethanol 
o 0.01% (w/v) bromophenol blue 
o ddH2O (10 mL final volume) 
- Store at 4° C 
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Protocol 
Sample Preparation 
1. Retrieve all tissue homogenates from –80° C storage, and immediately place in 
liquid nitrogen before handling. Let thaw and immediately place on ice. 
2. Based upon previously collected protein quantification results, aliquot 500 µg of 
protein per sample into individual eppendorf tubes. 
 Refer to Appendix 1d: Bradford Method. 
(Hint: vortex all samples thoroughly in order to ensure that a homogeneous 
mixture of whole tissue extract is drawn for immunoprecipitation.) 
3. Load all 500 µg samples with 40 µL of anti–phosphoserine primary antibody. 
 Refer to Appendix 2: Calculations. 
4. Fill the remaining volume of each eppendorf tube with additional lysis buffer. 
 Refer to Appendix 1c: Homogenization of Whole Tissue, for the 
preparation of lysis buffer. 
(Hint: previous trials excluding step #4 have led to the accumulation of sample 
debris along the inner walls of eppendorf tubes. With prolonged agitation, some 
contents of the immunoprecipitation samples are being shaken out of solution. 
This debris, the contents of which are unspecified, clings to the walls of the 
eppendorf and does not reach the pellet with centrifugation. Filling the dead space 
within each eppendorf tube with lysis buffer prevents this accumulation without a) 
altering protein concentrations within the sample, and b) disturbing any 
interactions between proteins of interest, primary antibody and agarose beads. As 
a result of this adjustment, it can be stated with increased confidence that all 
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proteins of interest are reaching the immunoprecipitated pellet post–
centrifugation.) 
5. Incubate all samples for 24 hours at 4° C with gentle agitation. 
6. Upon recommencement, load all samples with 20 µL of agarose bead suspension. 
7. Incubate all samples for 24 hours at 4° C with gentle agitation. 
Sample Cleaning 
8. Centrifuge all samples at 4° C at 13,000 rpm for 5 minutes. 
9. Using a syringe and needle, aspirate and discard all supernatants. 
(Hint: depending on the application of the immunoprecipitation method, the 
supernatant may need to be retained and analyzed in order to ensure that all 
protein of interest has been collected in the pellet. The use of this method in the 
current study aims to collect all phosphorylated pyruvate dehydrogenase 
phosphatase (PDP) proteins. Dephosphorylated PDP will be present in the 
supernatant and is not of interest for subsequent analysis. Therefore, in this 
instance, the supernatant can be discarded. 
10. Load all samples with 200 µL of 1x PBS. Gently resuspend pellets. 
11. Repeat steps 8–10 twice more, for a total of three 1x PBS washes. 
12. Once supernatants have been aspirated after the final wash, load all samples with 
80 µL of 2x sample buffer. 
13. Samples are now prepared for gel electrophoresis. Keep samples on ice for 
immediate use, however samples can be frozen at –80° C for next day use. 
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Appendix 1f. Western Blotting: Polyacrylamide Gel Electrophoresis 
 
Materials & Apparatus 
 
• Chemicals 
- 30% Acrylamide/bis–acrylamide solution 
- Ammonium persulfate (APS) 
- Glycine 
- Hydrochloric acid (HCl) 
- Methanol 
- Resolving gel buffer 
- Sodium chloride (NaCl) 
- Sodium dodecyl sulfate (SDS) 
- Sodium hydroxide (NaOH) 
- Stacking gel buffer 
- Tetramethylethylenediamine (TEMED) 
- Tris base 
- Tween 20 
• Mini–PROTEAN Tetra Cell electrophoresis kit 
- Casting frame 
- Casting stand 
- Electrode assembly 
- Mini tank & lid 
- PowerPac power supply  
- Rubber gasket 
- Short plate 
- Spacer plate 
- 10–lane gel combs 
• Western blot development materials 
- Horseradish peroxidase chemiluminescent substrate 
- ImageJ imaging software 
- Polyvinylidene fluoride (PVDF) membrane 
- Ponceau S Stain Solution 
- Primary antibody (specific against protein of interest) 
- Secondary antibody (horseradish peroxidase conjugated) 
- Western blot imaging system 
• Other 
- Disposable square petri dishes 
- Kaleidoscope protein standard 
- Non–fat dry skim milk 
- Protein transfer filters (pads & paper) 
- Rocking platform 
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Reagents 
 
1. 10% Ammonium Persulfate 
 
o 40 mg APS 
o ddH2O (400 µL final volume) 
- Make fresh before use 
- Measures sufficient volume for 2 gels 
 
2. 5% Blocking Solution 
 
o 5% (w/v) non–fat dry skim milk 
o 95% (v/v) TBST (100 mL final volume) 
- Make fresh before use 
- Measures sufficient to perform one experiment with 2 gels 
 
3. 10x Stock Electrode (Running) Buffer – pH 8.3 
 
o 250 mM tris base 
o 1.92 M glycine 
o 1% (w/v) SDS 
o ddH2O (1 L final volume) 
- Store at 4° C 
 
4. 1 M Hydrochloric Acid 
 
o 31.16 mL stock HCl (32.09 M) 
o 968.84 mL ddH2O 
- Store at room temperature with other acids 
 
5. 10% Sodium Dodecyl Sulfate 
 
o 50 g SDS 
o ddH2O (500 mL final volume) 
- Store at room temperature 
 
6. Sodium Hydroxide 
 
o 0.1 M NaOH 
o ddH2O (1 L final volume) 
- Store at room temperature 
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7. Transfer Buffer – pH 8.3 
 
o 31.25 mM tris base 
o 240 mM glycine 
o 10 mL 10% SDS 
o ddH2O (800 mL final volume) 
o 200 mL methanol 
- Make fresh before use 
 
8. 10x Stock Tris–Buffered Saline – pH 7.5 
 
o 200 mM tris base 
o 1.37 M NaCl 
o 38 mL 1M hydrochloric acid 
o ddH2O (1 L final volume) 
- Store at 4° C 
 
9. Tris–Buffered Saline with Tween (TBST) 
 
o 100 mL 10x TBS 
o 4 mL 25% Tween 20 
o ddH2O (1 L final volume) 
- Store at 4° C 
 
10. 25% Tween 20 
 
o 10 mL Tween 20 
o ddH2O (40 mL final volume) 
- Store at room temperature 
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Protocol 
Polyacrylamide Gel Preparation 
1. Retrieve spacer plates, short plates, casting frames and a casting stand in order to 
assemble glass cassette sandwiches to contain polyacrylamide gels. 
2. Line the protruding left and right edges of the spacer plate with ddH2O before 
introducing the short plate in order to obtain a tight seal between the glassware. 
3. Align both plates flush on a flat surface during assembly into the casting frame, 
ensuring that the borders of both glass plates are uniform. 
4. Engage both pressure cams of the casting frame, and place the frame into the 
casting stand with rubber gaskets in place at the floor of the stand. 
(Hint: Sliding 1 mL pipette tips behind the spring–loaded levers of the casting 
stand will provide added pressure and a tighter seal between glass plates and the 
rubber gasket. This addition, along with steps 3 & 4, will eliminate any risk of 
leakage while gel solutions are polymerizing in the casting stand.) 
5. Prepare separating and stacking polyacrylamide gels by mixing all ingredients, 
except for 10% APS and TEMED in 50 mL falcon tubes. 
Table A1.2. Volumes of all reagents required for the preparation of polyacrylamide gels 
in Western blotting. 
 
Gel Component 10% Separating Gel 6% Stacking Gel 
30% Acrylamide Solution 6.66 mL 2 mL 
Resolving Gel Buffer 5 mL --- 
Stacking Gel Buffer --- 2.5 mL 
ddH2O 7.92 mL 5.4 mL 
10% APS 200 µL 100 µL 
TEMED 20 µL 20 µL 
*Volumes listed are sufficient for 2 gels 
 
6. Insert a 10–lane comb between spacer and short plates, and mark a guideline 1 cm 
below the comb teeth. This will be the height to which separating gel is poured. 
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7. Immediately prior to pouring 10% separating solution into the cassette sandwich, 
add 10% APS and TEMED in order to initiate the gel polymerization reaction. 
8. Mix 10% separating solution rapidly with a transfer pipette, and proceed to pipette 
the solution into the sandwich up to the marked guideline. 
9. Overlay the separating solution with methanol in order to flatten the separating 
gel, and to eliminate bubbles remaining along the top surface of the solution. 
(Hint: eliminating any bubbles is crucial, as their presence can negatively affect 
sample loading and protein migration. Adhering to this tip is a good first step 
towards obtaining clean blots for protein quantification.) 
10. Once the separating gel has polymerized (~30 minutes), drain all methanol from 
the cassette. Proceed to rinse the gel surface with ddH2O. 
11. Repeat the same preparation for the 6% stacking solution with 10% APS and 
TEMED. Pipette this solution into the frame in order to fill the remaining volume. 
(Hint: pipette the stacking solution until it overflows out of the glass cassette. 
Doing so will force bubbles away from the top surface of the gel, as trapping 
bubbles within the stacking gel and sample wells is undesirable for clean blots. 
12. Insert a 10–lane comb into the cassette, and let the 6% stacking gel polymerize. 
Sample Processing – Protein Migration 
13. Retrieve previously prepared samples from storage and let thaw. Once thawed, 
keep samples on ice. 
14. Boil samples for 5 minutes, and store them on ice for 5 minutes before loading 
into gels. 
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15. Retrieve the electrode assembly for protein migration, and rest it on a clean flat 
surface with the clamping arms open. 
16. Retrieve glass cassettes containing polymerized gels from the casting stand, and 
insert them into the electrode assembly with short plates facing inward. 
(Hint: when working with an odd number of gels, a buffer dam must be used.) 
17. Close the clamping arms of the electrode assembly to produce a functional 
assembly. Apply firm pressure to the tops and sides of both cassettes during this 
process, in order to ensure that a leak–proof seal is achieved. 
18. Place the electrode assembly into the tank, and fill the inner chamber (space 
between both cassettes) with 1x running buffer until short plates are submerged. 
19. Remove lane combs and choose one well to load a kaleidoscope protein standard. 
20. Load samples into remaining wells with gel loading pipette tips. 
 For immunoprecipitated samples, pipette from the top suspension 
containing proteins of interest from the rest of the sample. After boiling, a 
clear separation within the sample can be seen with the lower fraction 
containing agarose beads and primary antibody, which must be avoided 
(Figure A1.6). 
 For whole tissue samples, vortex boiled samples thoroughly in order to 
obtain a homogenous mixture of whole homogenate, sample buffer and 
ddH2O. 
21. Fill the outer chamber of the tank with 550 mL of 1x running buffer. 
22. Place the lid onto the electrophoresis tank with the proper colour coding aligned, 
and insert the electrical leads into the power supply. 
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23. Run electrophoresis for 100 minutes with a 120–volt constant. 
Membrane Processing – Protein Transfer 
24. Retrieve the electrode assembly for protein transfer as well as a fresh tank. 
25. Cut PVDF membrane to the dimensions of the gel and rinse with methanol. 
26. Soak all transfer materials in freshly prepared transfer buffer to equilibrate before 
electrophoresis. 
27. Prepare the gel cassette sandwich in a shallow container filled with transfer buffer 
in the following order: 
- Clear side of the plastic cassette lying flat in the container 
 
- 1 pre–soaked foam pad 
 
- 1 pre–soaked filter pad (roll out bubbles with glass culture tube) 
 
- 2 pre–soaked filter papers (roll out bubbles with glass culture tube) 
 
- PVDF membrane 
 
- Equilibrated gel 
 
- 2 pre–soaked filter papers (roll out bubbles with glass culture tube) 
 
- 1 pre–soaked filter pad (roll out bubbles with glass culture tube) 
 
- 1 pre–soaked foam pad 
 
- Fold black side of the cassette over and lock sandwich in place 
 
28. Insert the gel cassette sandwich into the electrode assembly, ensuring that the 
black side of the cassette is inserted against the black side of the assembly. 
29. Place the electrode assembly into the tank, and fill the tank completely with 
transfer buffer. 
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30. Place the tank in a large enough container to surround it with ice. Add an ice pack 
into the electrophoresis tank in order to complete the cooling unit. 
31. Place a stir bar into the tank in order to maintain even cooling throughout the 
transfer. 
32. Place the lid onto the electrophoresis tank with the proper colour coding aligned, 
and insert the electrical leads into the power supply. 
33. Run electrophoresis for 60 minutes with a 100–volt constant. 
Membrane Processing – Protein Staining 
34. Place the membrane in a disposable square petri dish with the proteins facing 
upward. 
35. Add 10 mL of Ponceau S solution in order to stain protein bands. 
36. Place the petri dish onto the rocking device, and periodically observe the 
membrane until stained bands are visualized clearly (~5 minutes). 
37. Pour off Ponceau S solution. Rinse the membrane in 10 mL of TBST to wash off 
any excess staining solution. Repeat TBST wash twice more. 
38. Pour off TBST. Immediately save a visual for a reference of total protein content 
in each lane using transparent film. 
(Hint: this step is crucial towards eliminating any error that may have occurred 
during sample loading. Protein of interest contents must be normalized to total 
protein contents in order to control for any error during sample loading.) 
39. Proceed to reverse staining through the addition of 10 mL 0.1 M NaOH. 
40. Pour off NaOH. Rinse the membrane in 10 mL ddH2O for 5 minutes, and repeat 
this rinse another two times. 
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Membrane Processing – Blocking 
41. Place the membrane in a clean square petri dish, and add 10 mL of freshly 
prepared 5% blocking solution. Cover the dish with Parafilm & lid. 
42. Place the petri dish onto the rocking device, and proceed to block the membrane 
at room temperature for 1 hour. 
(Hint: blocking is essential towards eliminating non–specific protein interactions 
throughout blot development. The target and both antibodies are all proteins, and 
blocking assists in the assurance that proper binding occurs between these 
molecules. Diluted proteins in the skim milk attach to the membrane in all places 
where target proteins are not bound. Once antibody is introduced, all binding sites 
are filled except for those on the target protein of interest.) 
Membrane Processing – Blot Development 
43. Prepare primary antibody incubating solution, against the target protein of interest, 
in a clean square petri dish. 
44. Remove the membrane from the blocking solution, and wash it with 10 mL of 
TBST for 5 minutes. Repeat TBST was twice more. 
45. Place the membrane into the petri dish containing primary incubating solution. 
46. Cover the square petri dish with Parafilm® & lid, and incubate overnight at 4° C 
with gentle agitation. This step concludes day one of the experiment. 
47. Recommence experiment on day two. Pour off primary incubating solution, and 
wash the membrane with 10 mL TBST for 5 minutes. Repeat wash two times. 
48. Prepare secondary antibody incubating solution, against the primary antibody, in a 
clean square petri dish. 
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49. Place the membrane into the dish containing secondary incubating solution. Cover 
the dish with Parafilm® & lid, and incubate for 1–2 hours at room temperature. 
50. Pour off secondary incubating solution, and perform a 3 x 5 minute TBST wash. 
Dry the membrane as much as possible, without interfering or making any contact 
with the protein side of the membrane, before introducing chemiluminescent 
reagent. 
51. After the third wash, pour off TBST and baste the membrane with 2 mL of 
chemiluminescent substrate for 3 minutes. Once again, dry the membrane as much 
as possible. 
52. Place the membrane between two sheets of transparent film in preparation for 
development and protein visualization. 
53. Place the protected membrane into the imaging station and develop the membrane 
according to pre–determined exposure settings. 
54. Save a visual for a reference of protein content in each lane. Quantify protein of 
interest contents using ImageJ software. 
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Figure A1.6. Separation within immunoprecipitated samples after boiling in preparation 
for Western blotting. 
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Figure A1.7. Full Western blot of phosphorylated Akt (pAkt, 60 kDa) protein in extensor 
digitorum longus skeletal muscle tissue. 
 
 
 
Figure A1.8. Full Western blot of immunoprecipitated serine–phosphorylated pyruvate 
dehydrogenase phosphatase 1 (pPDP1, 53 kDa) protein in extensor digitorum longus 
skeletal muscle tissue. 
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Figure A1.9. Full Western blot of protein kinase C–delta (PKCδ, 78 kDa) protein in 
mitochondrial subfractions from extensor digitorum longus skeletal muscle tissue.  
 
 
 
Figure A1.10. Full Western blot of cytochrome c oxidase subunit 4 (CoxIV, 18 kDa) 
protein in mitochondrial subfractions from extensor digitorum longus skeletal muscle 
tissue.  
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Appendix 1g. PDHa Activity Assay by Measurement of Acetyl–CoA Accumulation 
 
Materials & Apparatus 
 
• Coenzyme A (CoA) 
• Dichloroacetic acid (DCA) 
• Ethylenediaminetetraacetic acid (EDTA) 
• Ethylene glycol tetraacetic acid (EGTA) 
• Magnesium chloride (MgCl2) 
• Nicotinamide adenine dinucleotide (NAD+) 
• Perchloric acid (PCA) 
• Potassium bicarbonate (KHCO3) 
• Potassium chloride (KCl) 
• Pyruvate 
• Sodium fluoride (NaF) 
• Sucrose 
• Thiamine pyrophosphate (TPP) 
• Tris base 
• Tris hydrochloride (Tris HCl) 
• Triton X–100 
• Block heater 
• Glass tissue grinders 
• Motor driven homogenizer 
• 12 x 75 mm culture tubes 
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Reagents 
 
1. Coenzyme A 
 
o 13 mM CoA 
o ddH2O (2.5 mL final volume) 
- Make fresh before use 
 
2. Nicotinamide Adenine Dinucleotide 
 
o 39 mM NAD+ 
o ddH2O (2.5 mL final volume) 
- Make fresh before use 
 
3. PDHa Assay Buffer – pH 7.8 
 
o 144.4 mM Tris base 
o 1.44 mM MgCl2 
o 0.72 mM EDTA 
o ddH2O (100 mL final volume) 
- Aliquot into 10 mL portions 
- Store aliquots at –20° C 
 
4. PDHa Homogenizing Buffer – pH 7.8 
 
o 50 mM Tris HCl 
o 200 mM Sucrose 
o 50 mM KCl 
o 50 mM NaF 
o 5 mM DCA 
o 5 mM MgCl2 
o 5 mM EGTA 
o 0.1% (v/v) Triton X–100 
o ddH2O (100 mL final volume) 
- Aliquot into 1.5 mL portions 
- Store aliquots at –20° C 
 
5. PDHa Incubating Solution 
 
o 8.33% (v/v) 39 mM NAD+ 
o 8.33% (v/v) 13 mM CoA 
o 8.33% (v/v) 13 mM TPP 
o 75% (v/v) PDHa assay buffer 
- Make fresh before use 
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6. 0.5 M Perchloric Acid 
 
o 1.45 mL Stock PCA (86.2 M) 
o ddH2O (250 mL final volume) 
- Store at 4° C 
 
7. Potassium Bicarbonate 
 
o 2.2 M KHCO3 
o ddH2O (40 mL final volume) 
- Store at 4° C 
 
8. Pyruvate 
o 26 mM pyruvate 
o ddH2O (1.25 mL final volume) 
- Make fresh before use 
 
9. Thiamine Pyrophosphate 
o 13 mM TPP 
o ddH2O (2.5 mL final volume) 
- Make fresh before use 
  
M.Sc. Thesis – J. R. Choptiany  Brock University 
 118 
Protocol 
PDHa Homogenization Procedure 
1. Retrieve all muscle samples from –80° C storage and place in liquid nitrogen. 
2. Place a base volume of PDHa homogenizing buffer into a homogenizing potter 
(Example: 500 µL). 
3. Using a foam stand for support, place the potter onto a weight scale and tare the 
scale. 
4. Add a piece of wet frozen EDL muscle to the potter and record its weight in 
milligrams. 
(Hint: be sure to work quickly and ensure that the tissue sample does not thaw.) 
5. Immediately begin homogenization of the sample, gently by hand with the potter 
on ice at all times. 
(Hint: it is imperative to introduce the tissue to kinase (DCA) and phosphatase 
(NaF) inhibitors as soon as possible, in order to lock the phosphorylation state of 
the sample.) 
6. Keep the potter on ice, and calculate the remaining volume of homogenizing 
buffer required in order to produce a 30–fold dilute homogenate. 
(Example: 30 mg of skeletal muscle tissue within 900 µL of PDHa homogenizing 
buffer.) 
7. Add the remaining buffer to achieve the desired dilution (Example: 400 µL). 
8. Continue to homogenize the sample on ice with a motor driven glass pestle for 50 
seconds at 400 rpm. 
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9. While using the motor driven homogenizer, periodically check the potter to 
ensure that the entire tissue sample is being processed. 
10. Continue homogenizing until an opaque homogenate is produced. 
(Hint: when held up to light with the pestle fully depressed into the potter, large 
connective debris should be the only visible material left unprocessed.) 
11. Place the homogenate in a labeled eppendorf tube and snap–freeze in liquid 
nitrogen as quickly as possible. The sample is now prepared for analysis of PDHa 
activity. 
(Hint: it is crucial to snap freeze the sample as soon as possible, as cellular 
contents will reform within solution at room temperature that contain the PDH 
complex. If this reformation occurs, resulting PDHa activities will be lower than 
expected.) 
Assay Preparation 
12. Pre–heat a block heater 37° C, and use a thermometer to ensure temperature 
maintenance throughout the assay. 
13. Retrieve a sufficient volume of PDHa assay buffer from –20° C storage. 
14. Prepare and combine all reagents included in the PDHa incubating solution. 
• 2.5 mL 13 mM CoA 
• 2.5 mL 39 mM NAD+ 
• 2.5 mL 13 mM TPP 
• 22.5 mL PDHa assay buffer 
15. Prepare and pre–warm (37 °C) 1.25 mL 26 mM pyruvate in an eppendorf tube. 
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16. Label three glass culture tubes for every sample to be assayed. 
• Samples are run in duplicate (A & B), in addition to a blank (C). 
17. Label nine eppendorf tubes for every sample to be assayed. 
• 1, 2 and 3 minute time points for muscle samples A, B and C. 
18. Pre–load 40 µL of 0.5 M PCA into each of the labeled eppendorf tubes. 
19. Pipette 720 µL of PDHa incubating solution into each culture tube of the first 
muscle sample to be processed. Pre–warm the culture tubes in the block heater. 
PDHa Assay 
20. Using a positive displacement pipette, add 30 µL of homogenate into the culture 
tubes. Gently vortex each tube. 
(Hint: thaw each homogenate on at a time immediately prior to analysis to prevent 
sample warming.) 
21. Initiate the PDH reaction by adding 30 µL of 26 mM pyruvate, and gently vortex 
the culture tube after doing so. Return sample to the block heater and start a timer. 
(Hint: blank reactions are initiated with ddH2O, replacing 26 mM pyruvate.) 
22. After precisely 1 minute, withdraw 200 µL of the incubation mixture and pipette 
into the appropriately labeled eppendorf tube pre–loaded with 0.5 M PCA. Vortex 
the acidified aliquot, and store at one ice until the completion of the trial. 
23. Repeat step #22 at 2 and 3–minute intervals to obtain three aliquots to be analyzed 
for the determination of the PDHa reaction rate. 
24. Repeat steps #19 through 23 for all samples (duplicates and blanks). 
25. Keep acidified samples on ice for a minimum of 5 minutes. 
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26. After 5 minutes, neutralize each sample through the addition of 10 µL of 1 M 
KHCO3. 
27. Allow all neutralized samples to sit for 5 minutes at room temperature. 
28. Store all samples at –80 °C for future acetyl–CoA analysis. 
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Appendix 1h. Determination of Acetyl–CoA Accumulation 
 
Materials & Apparatus 
 
• Acetyl–CoA 
• Alpha–ketoglutaric acid (α–KG) 
• Aspartate transaminase (AST) 
• Aspartate: 14C radiochemical 
• Citrate synthase (CS) 
• Copper sulfate (CuSO4) 
• Dithiothreitol (DTT) 
• Dowex cation exchange resin 
• Ethylenediaminetetraacetic acid (EDTA) 
• N–ethylmaleimide (NEM) 
• N–[2–Hydroxyethyl]–piperazineethanesulfonic acid (HEPES) 
• Perchloric acid (PCA) 
• Potassium acetate (K–acetate) 
• Potassium glutamate (K–glut) 
• Potassium hydroxide (KOH) 
• Scintillation cocktail fluid 
• 12 x 75 mm culture tubes 
• Scintillation counter 
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Reagents 
 
1. Acetyl–CoA Assay Buffer 
 
o 9% (v/v) 0.1 M DTT 
o 34.125% (v/v) 1 mM CuSO4 
o 34.125% (v/v) 400 mM potassium acetate 
o 22.75% (v/v) ddH2O 
- Make fresh before use 
 
2. Acetyl–CoA 
 
o 2 mM Acetyl–CoA 
o ddH2O (10 mL final volume) 
- Dilute into 2 µM aliquots for individual trial use 
- Store aliquots at –20° C  
 
3. α–Ketoglutaric Acid 
 
o 8 mM α–KG 
o ddH2O (10 mL final volume) 
- Make fresh before use 
 
4. 40 µM 14C–Aspartate 
 
o 200 µL Stock 14C–Aspartate 
o ddH2O (1 mL final volume) 
- Store at 4° C 
 
5. 1:10 Aspartate Transaminase 
 
o 9% (v/v) AST 
o 91% (v/v) ddH2O 
- Aliquot into 200 µL portions 
- Store aliquots at –20° C 
 
6. 1:10 Citrate Synthase 
 
o 9% (v/v) CS 
o 91% (v/v) ddH2O 
- Aliquot into 500 µL portions 
- Store aliquots at –20° C 
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7. Copper Sulfate 
 
o 1 mM CuSO4 
o ddH2O (50 mL final volume) 
- Aliquot into 1 mL portions 
- Store aliquots at –20° C 
 
8. Dithiothreitol 
 
o 100 mM DTT 
o ddH2O (10 mL final volume) 
- Aliquot into 500 µL portions 
- Store aliquots at –20° C 
 
9. Dowex Cation Resin 
 
o 37.5% (w/v) Dowex 
o 62.5% (v/v) ddH2O 
- Store at room temperature 
 
10. Ethylenediaminetetraacetic acid 
 
o 11 mM EDTA 
o ddH2O (50 mL final volume) 
- Aliquot into 1 mL portions 
- Store aliquots at –20° C  
 
11. Ethylenediaminetetraacetic acid 
 
o 60 mM EDTA 
o ddH2O (50 mL final volume) 
- Aliquot into 1 mL portions 
- Store aliquots at –20° C 
 
12. N–ethylmaleimide 
 
o 30 mM NEM 
o ddH2O (50 mL final volume) 
- Aliquot into 1 mL portions 
- Store aliquots at –20° C 
 
13. N–(2–Hydroxyethyl)–piperazine–N’–(2–ethanesulfonic acid) – pH 7.4 
 
o 500 mM HEPES 
o ddH2O (100 mL final volume) 
- Store at 4° C 
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14. 1 M Perchloric Acid 
 
o 1.16 mL Stock PCA (86.2 M) 
o ddH2O (100 mL final volume) 
- Store at 4° C 
 
15. Potassium Acetate 
 
o 400 mM potassium acetate 
o ddH2O (50 mL final volume) 
- Aliquot into 1 mL portions 
- Store aliquots at –20° C 
 
16. Potassium Hydroxide 
 
o 600 mM KOH 
o ddH2O (100 mL final volume) 
- Store at 4° C 
 
17. Potassium Glutamate 
 
o 178 mM K–glut 
o ddH2O (50 mL final volume) 
- Aliquot into 1 mL portions 
- Store aliquots at –20° C  
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Protocol 
Assay Preparation 
1. Thaw neutralized PDHa samples and place them on ice. 
2. Label glass culture tubes for all samples to be assayed as well as acetyl–CoA 
standards. 
3. Prepare acetyl–CoA standards in duplicate. 
Table A1.3. Volumes of Acetyl–CoA and ddH2O required for the preparation of the 
Acetyl–CoA assay standard solutions. 
 
Concentration 
(mM) 
2 µM Acetyl–CoA 
(µL)  
ddH2O 
(µL) 
Total Volume 
(µL) 
0 0 220 220 
40 4 216 220 
125 12.5 207.5 220 
250 25 195 220 
375 37.5 182.5 220 
500 50 170 220 
 
4. Load all culture tubes assigned to PDHa samples with 200 µL of ddH2O. 
5. Load 20 µL of neutralized PDHa samples into respective culture tubes. 
6. Prepare acetyl–CoA assay buffer consisting of 0.1 M DTT, 1 mM CuSO4, 400 
mM K–acetate and ddH2O. 
 Premix 1 mM CuSO4, 400 mM K–acetate and ddH2O in a 3:3:2 ratio.  
Table A1.4. Volume of Acetyl–CoA buffers required per number of samples processed. 
 Number of Culture Tubes 
Reagent µL/tube 30 40 60 80 100 
0.1 M DTT 2 60 80 120 160 200 
CuSO4–K–acetate–
ddH2O 
(3:3:2) 
 
20 
 
600 
 
800 
 
 
1200 
 
1600 
 
2000 
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Acetyl–CoA Assay 
7. Add 20 µL of acetyl–CoA assay buffer to each culture tube. Vortex all samples, 
and incubate at room temperature for 30 minutes. 
8. Prepare the radiolabeled 14C–oxaloacetate reaction during this incubation. Refer 
to ‘Preparation of Radiolabeled 14C–oxaloacetate’ (page 137). 
9. Once the assay buffer incubation has concluded, add 20 µL of 60 mM EDTA to 
each culture tube. Vortex all samples, and incubate at room temperature for 5 
minutes. 
10. Following the 60 mM EDTA incubation, add 30 µL of 30 mM NEM to each 
culture tube. Vortex all samples, and incubate at room temperature for 5 minutes. 
11. Following the 30 mM NEM incubation, add 20 µL of radiolabeled 14C–
oxaloacetate and 10 µL of 1:10 citrate synthase to each culture tube. Vortex all 
samples, and incubate at room temperature for 20 minutes. 
Key Reaction #2 
14C–oxaloacetate + acetyl–CoA   CS   14C–citrate + CoA 
(Significance: radiolabeled citrate is produced from 14C–oxaloacetate and existing 
concentrations of acetyl–CoA within each sample. This reaction enables the 
eventual counting of radiolabeled citrate, which will reflect each sample’s acetyl–
CoA concentration.) 
12. Prepare the transamination reagent during this incubation. Refer to ‘Preparation of 
Transamination Reagent’ (page 139). 
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13. Following the 14C–oxaloacetate and citrate synthase incubation, add 30 µL of the 
transamination reagent to each culture tube. Vortex all samples, and incubate at 
room temperature for 20 minutes. 
Key Reaction #3 
14C–oxaloacetate + glutamate   AST   14C–aspartate + α–ketoglutarate 
(Significance: reversing reaction #1 with transamination reagent enables the 
isolation of negatively charged 14C–citrate molecules. At this point in the assay, 
all samples contain radiolabeled citrate as well as any leftover radiolabeled 
oxaloacetate that was not processed in the citrate synthase reaction. Both 14C–
citrate and 14C–oxaloacetate contain negatively charged ketone groups and if left 
alone in each sample, all labeled carbons would eventually be detected in 
scintillation counting, which would not be reflective of each sample’s acetyl–CoA 
concentrations. Therefore, all remaining 14C–oxaloacetate is reprocessed into 14C–
aspartate, which contains positively charged amine groups. All positively charge 
radiolabeled molecules will eventually be separated from the sample, leaving a 
purified extract containing negatively charged 14C–citrate. 
14. Prepare the Dowex cation exchange resin during this incubation. 
15. Prepare one 20 mL scintillation vial for each sample with appropriate labeling 
during this incubation, and load 5 mL of scintillation cocktail fluid to each vial. 
16. Following the transamination reagent incubation, add 1 mL of Dowex cation 
exchange resin to each culture tube. Cap every sample tightly and invert by hand 
for 2 minutes. 
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(Hint: the addition of ion exchange resin will separate all samples by charge, 
which will isolate positively and negatively charged radiolabeled molecules into 
separate fractions.) 
17. Centrifuge all samples at 3,000 rpm for 2 minutes at room temperature. 
18. Aspirate 500 µL of the supernatant from each sample, and deposit into respective 
scintillation vials. Tightly seal and shake all vials for thorough mixing. 
(Hint: the supernatant is the fraction of the sample that contains negatively 
charged 14C–citrate, which reflects each sample’s acetyl–CoA concentration.) 
19. Count each sample in a liquid scintillation counter to quantify ionizing radiation 
from each sample. 
20. Calculate PDHa activity for each sample (mmol/minute/kg wet weight tissue) 
based upon ionization counts per minute. 
 Refer to Appendix 2: Calculations. 
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Preparation of Radiolabeled 14C–Oxaloacetate 
1. Combine the following ingredients in an eppendorf tube. Appropriate volumes 
must be determined based upon the number of samples involved. 
Table A1.5. Volume of reagents required for radiolabel preparation per number of 
samples processed. 
 
 Number of Culture Tubes 
Reagent µL/Tube 30 40 60 80 100 
0.5 M HEPES 0.67 20.1 26.8 40.2 53.6 67 
11 mM EDTA 1 30 40 60 80 100 
(1:10) AST* 0.33 9.9 13.2 19.8 26.4 33 
8 mM α–KG** 0.67 20.1 26.8 40.2 53.6 67 
40 µM 14C–Aspartate** 3.33 99.9 133.2 199.8 266.4 333 
* Enzyme involved in key reaction #1 
** Reactant involved in key reaction #1 
2. Incubate reagents for 10 minutes at room temperature for reaction to proceed. 
Key Reaction #1 
14C–aspartate + α–ketoglutarate   AST   14C–oxaloacetate + glutamate 
(Significance: preparing radiolabeled oxaloacetate from 14C–aspartate enables the assay 
to utilize existing concentrations of acetyl–CoA within each sample. The end goal of the 
assay is to count each sample’s concentration of radiolabeled citrate, which is reflective 
of acetyl–CoA concentrations.) 
Table A1.6. Volume of PCA required for radiolabel preparation per number of samples 
processed. 
 
 Number of Culture Tubes 
Reagent µL/Tube 30 40 60 80 100 
1 M PCA 0.67 20.1 26.8 40.2 53.6 67 
 
3. Incubate acidified reagents for 10 minutes on ice to halt the reaction. 
4. Upon the completion of this second incubation, neutralize reagents through the 
addition of a base (600 mM KOH). 
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Table A1.9. Volume of KOH and EDTA required for radiolabel preparation per number 
of samples processed. 
 
 Number of Culture Tubes 
Reagent µL/Tube 30 40 60 80 100 
6 00 mM KOH 1.33 39.9 53.2 79.8 106.4 133 
11 mM EDTA 12 360 480 720 960 1200 
 
5. Store this preparation on ice for a minimum of 5 minutes before integration into 
the acetyl–CoA assay. 
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Preparation of Transamination Reagent 
1. Combine the following ingredients in an eppendorf tube. Appropriate volumes 
must be determined based upon the number of samples involved. 
Table A1.8. Volume of reagents required for transamination reagent preparation per 
number of samples to be assayed. 
 
 Number of Culture Tubes 
Reagent µL/Tube 30 40 60 80 100 
178 mM K–glut** 30 900 1200 1800 2400 3000 
(1:10) AST* 3.33 99.9 133.2 199.8 266.4 333 
ddH2O 6.66 199.8 266.4 399.6 532.8 666 
* Enzyme involved in key reaction #3 
** Reactant involved in key reaction #3 
2. Store this preparation on ice prior to integration into the acetyl–CoA assay. 
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Appendix 1i. Citrate Synthase Activity Assay 
 
Materials & Apparatus 
 
• Acetyl–CoA 
• Bovine serum albumin (BSA) 
• 5,5’–dithiobis[2–nitrobenzoic acid] (DTNB) 
• Oxaloacetic acid 
• Potassium phosphate (KH2PO4) 
• Tris base 
• Triton–X 100 
• Blackened sidewall microcuvettes 
• Glass tissue grinders 
• Spectrophotometer 
 
Reagents 
 
1. Citrate Synthase Homogenizing Buffer – pH 7.3 
 
o 0.1 M KH2PO4 
o 0.05% (w/v) BSA 
o ddH2O (100 mL final volume) 
- Store at 4° C 
 
2. Tris Buffer – pH 8.3 
 
o 100 mM Tris base 
o ddH2O (250 mL final volume) 
- Store at 4° C 
 
3. 5,5’–dithiobis [2–nitrobenzoic acid] 
 
o 1 mM DTNB 
o Tris Buffer (10 mL final volume) 
- Store at 4° C 
- Must be stored in opaque container 
- Fresh reagent required every 1–2 weeks 
 
4. Acetyl–CoA 
 
o 3 mM Acetyl–CoA 
o ddH2O (5 mL final volume) 
- Aliquot into 200 µL portions 
- Freeze aliquots at –80° C 
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5. 10% Triton 
 
o 10% (v/v) Triton–X 100 
o 90% (v/v) ddH2O (1 mL final volume) 
- Store at 4° C 
 
6. Oxaloacetic Acid 
 
o 10 mM Oxaloacetic acid 
o Tris Buffer (1 mL final volume) 
- Prepare fresh daily 
- Store on ice throughout assay 
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Protocol 
Tissue Homogenization 
1. Gather tissue grinders and citrate synthase homogenizing buffer from storage and 
place these materials on ice. Allow sufficient time for cooling before processing 
any tissue samples. 
(Hint: keep the homogenizing pestle inside the potter to avoid water 
contamination within the homogenization apparatus.) 
2. Retrieve EDL tissue chunks from –80° C storage and immediately place in liquid 
nitrogen prior to handling. 
 Refer to Appendix 1b: Mitochondrial isolations. 
3. Using a foam stand for support, place a base volume of buffer into the 
homogenizing potter (Example: 500 µL). 
4. Place the potter onto a weigh scale and tare the scale. 
5. Drop the frozen chunk of EDL tissue into the potter. Allow for the scale to settle 
and record the weight of the tissue. 
6. Calculate the remaining volume of homogenization buffer required in order to 
produce a 100–fold dilute homogenate (Example: 10 mg chunk within 1 mL of 
homogenizing buffer). 
7. Place the potter back on ice, and add the remaining buffer (Example: 500 µL). 
8. Rigorously homogenize the tissue on ice at all times until an opaque homogenate 
is produced. 
(Hint: some homogenization procedures require gentle tissue grinding, however 
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the citrate synthase assay requires mitochondrial contents to be suspended in 
solution. Therefore, rigorous tissue grinding is permissible in this instance.) 
9. Snap–freeze samples in liquid nitrogen. Store citrate synthase whole homogenate 
in a labeled eppendorf at –80° C.  
(Hint: samples need to be frozen and thawed three times in order to release 
mitochondrial contents for enzyme activity analysis.) 
Citrate Synthase Assay 
10. Retrieve samples (citrate synthase whole homogenates or mitochondrial total 
suspensions) and acetyl–CoA from –80° C storage. Immediately place on ice once 
thawed. 
11. Retrieve tris buffer, DTNB, and 10% triton from 4° C storage and immediately 
place on ice. 
12. Prepare fresh oxaloacetic acid and immediately place on ice. 
13. Prepare as many samples as desired with tris buffer, DTNB, acetyl–CoA and 10% 
triton. 
(Hint: spectrophotometer can run a maximum of 8 samples per trial.) 
Table A1.9. Volume of reagents required for the preparation of citrate synthase assay 
samples. 
 
 Number of samples to assay 
Reagent µL per cuvette 2 8 16 
Tris buffer 150 325 µL 1300 µL 2500 µL 
DTNB 25 60 µL 225 µL 425 µL 
Acetyl–CoA 40 80 µL 320 µL 640 µL 
10% Triton 10 25 µL 100 µL 175 µL 
 
14. Turn on the spectrophotometer and open the SwiftII software program. 
15. Open the reaction kinetics function, and select the citrate synthase software 
procedure. 
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(Hint: the following steps of the assay must be performed diligently with haste. If 
inexperienced with the assay protocol, practice with a small number of samples 
before becoming accustomed to the required pace. Process more samples per trial 
once confident with the execution of the assay. It is crucial to have the assay 
software set up and one click away from running before continuing sample 
preparation.) 
16. Working as quickly and accurately as possible, add 15 µL of oxaloacetic acid to 
each microcuvette. Mix the samples thoroughly with clean stir sticks. 
17. Load all samples (maximum of 8) into the spectrophotometer and close the lid. 
(Hint: if using microcuvettes, the cuvette cannot be depressed all the way down 
into the sample chamber. This causes the transmission of light to pass over and 
miss the intended sample; consequently no change in absorbance will be recorded 
as the assay progresses. Only depress the cuvette so far that the top edge of the 
cuvette rests flush against the top edge of the sample chamber). 
18. Run the citrate synthase assay. Ensure that the absorbance set to 412 nm. 
References 
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Appendix 1j. Pyruvate Dehydrogenase Phosphatase Activity Assay 
 
Materials & Apparatus 
 
• Bovine serum albumin (BSA) 
• Ethylenediaminetetraacetic acid (EDTA) 
• Ethylene glycol tetraacetic acid (EGTA) 
• Imidazole 
• Magnesium chloride (MgCl2) 
• Mannitol 
• 2–mercaptoethanol 
• PDH E1α phosphopeptide 
• Phosphatase inhibitor 
• Serine/Threonine Phosphatase Assay System (Promega; Catalog # V2460) 
- Molybdate dye additive 
- Molybdate dye solution 
- Phosphate free water 
- Phosphate standard 
- Spin columns 
• Sodium azide 
• Sucrose 
• Tris base 
• Tris hydrochloride (Tris HCl) 
• Centrifuge 
• Skirted microtiter 96–well plate 
• Spectrophotometer 
 
Reagents 
 
1. Sucrose & Mannitol (pH 7.4) 
 
o 220 mM Sucrose 
o 70 mM Mannitol 
o 10 mM Tris HCl 
o 0.1 mM EDTA 
o ddH2O (100 mL final volume) 
- Store at 4° C 
 
2. Column Storage Buffer 
 
o 10 mM Tris base (pH 7.5) 
o 1 mM EDTA 
o 0.02% (w/v) Sodium azide 
o ddH2O (1 L final volume) 
- Store at 4° C 
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3. 5X PDP Assay Reaction Buffer 
 
o 250 mM Imidazole (pH 7.2) 
o 1 mM EGTA 
o 25 mM MgCl2 
o 0.1% (v/v) 2–mercaptoethanol 
o 0.05% (w/v) BSA 
o ddH2O (100 mL final volume) 
- Aliquot into 200 µL portions 
- Store aliquots at –80° C 
 
4. Stock Phosphatase Assay Standard 
 
o 5% (v/v) Phosphate standard 
o 95% (v/v) Phosphate free water 
- Prepare fresh before use 
- Store on ice 
 
5. PDH E1α Phosphopeptide 
 
o 1.5 mM Phosphopeptide 
o Phosphate free water (100 µL final volume) 
- Prepare fresh before use 
- Store on ice 
 
6. Molybdate Dye Mixture 
 
o 1% (v/v) Molybdate dye additive 
o 99% (v/v) Molybdate dye solution 
- Prepare fresh before use 
- Store on ice 
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Protocol 
Sample Preparation 
1. Perform a Bradford Assay in order to determine the protein concentration of all 
mitochondrial extracts. 
 Refer to Appendix 1d: Bradford Method. 
2. Dilute all samples with sucrose & mannitol to a final protein concentration of 2 
µg/µL and a total volume of 30 µL. 
3. Immediate snap–freeze 2 µg/µL samples in liquid nitrogen. Return leftover 
mitochondrial extracts to –80° C storage. 
4. Freeze–thaw working samples in liquid nitrogen 3 times in order to lyse 
mitochondrial membranes. 
(Hint: samples need to be frozen and thawed in order to release mitochondrial 
contents for enzyme activity analysis.) 
5. Spin samples at 21,000 x g for 1 hour at 4° C in order to pellet out bulky 
membrane proteins. Retain supernatants and transfer to clean eppendorfs for use 
in the PDP assay. Immediately store samples on ice.  
Spin Column Preparation 
6. Insert spin columns into spare 50 mL falcon tubes (collection reservoirs), and load 
spin columns with 10 mL of ddH2O. 
(Hint: if ddH2O does not filter through spin columns by gravity, remove columns 
from the falcon tubes and discard ddH2O previously added to the spin column. 
Proceed to wet the underside of the glass filter using a 200 µL pipette and ~300 
µL of ddH2O. Once absorbed, reassemble the spin columns in falcon tubes and 
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reload 10 mL of ddH2O into the columns. The spin columns should now begin 
draining by gravity. Gentle agitation or tapping may be required to start this 
process.) 
7. Resuspend sephadex G–25 beads with a 5 mL pipette tip and load 10 mL into 
each spin column. Allow flow through to drain by gravity. 
8. With the filtered sephadex now resting in the columns, load 10 mL of column 
storage buffer into each spin column. Allow flow through to drain by gravity. 
9. Centrifuge spin columns at 600 x g for 5 minutes at 4° C in order to remove 
excess buffer that is coating Sephadex beads. 
10. Place spin columns into fresh 50 mL falcon tubes. Load columns with diluted 
mitochondrial samples, and centrifuge at 600 x g for 5 minutes at 4° C in order to 
remove excess inorganic phosphate. Ensure that each falcon tube is appropriately 
labeled with each sample’s details. 
11. Retain samples and transfer into clean eppendorfs for application into the PDP 
assay. 
PDP Assay 
12. Prepare all assay reagents and store them on ice along with the purified 
mitochondrial samples. 
13. Before preparing any samples, pre–heat the plate reader to 37° C. 
(Hint: turn on the plate reader and open the KC4™ software. In the settings 
function, adjust the pre–heating setting to ‘on’ and type in the desired temperature. 
Click OK and proceed to the control function. Select the ‘pre–heat’ tab and re–
enter the desired temperature. Wait until the desired temperature has been reached, 
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which will only take a few minutes. The plate reader is now ready for the PDP 
assay.) 
14. Retrieve a 96–well plate, and begin assay preparation by setting up the phosphate 
standard. 
15. Dilute enough standard into phosphate–free water (1:19 ratio) to produce a large 
enough volume for the assay, which depends on the number of samples being 
processed. Furthermore, total volume is dependent upon whether the standard is to 
be run in singular, duplicate or triplicate wells. 
Table A1.12. Volume of stock phosphate standard and phosphate–free water required 
for the preparation of the PDP assay standard curve. 
 
Phosphate Standard 
Concentration (nM) 
Stock Phosphate Standard 
(µL) 
Phosphate–Free Water 
(µL) 
2 40 10 
1 20 30 
0.5 10 40 
0.2 4 46 
0.1 2 48 
0 0 50 
*Total volume of Stock Standard (76 µL) and Phosphate–Free Water (224 µL) are sufficient to 
run the phosphate standard in singular wells. 
 
16. Prepare sample and blank reaction mixtures directly into the 96–well plate. Like 
the phosphate standard, prepare enough materials to run as many wells as desired. 
17. Prior to the addition of the peptide, insert the well plate into the plate reader and 
allow all reaction mixtures to equilibrate to 37° C for 10 minutes. 
Table A1.13. Volume of PDP assay components required for individual reactions. 
 
PDP Assay 
Component 
Sample (µL) Sample Blank (µL) Phosphopeptide 
Blank (µL) 
5X Reaction Buffer 10 10 10 
Phosphatase Inhibitor 1 1 1 
Phosphate–free Water 21 26 34 
Mitochondrial Sample 5 0 5 
Phosphopeptide 13 13 0 
*Total volumes are sufficient to run samples in singular wells. 
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18. Once the equilibration phase has ended, remove the well plate from the plate 
reader and return to the lab bench. Add 13 µL of phosphopeptide to each well, 
aside from the peptide blanks, in order to initiate dephosphorylation reactions. 
19. Incubate the 96–well plate for 30 minutes at 37° C to allow all reactions to 
proceed. 
20. Once the incubation phase has ended, remove the well plate from the plate reader 
and return to the lab bench. Halt all reactions through the addition of 50 µL of 
molybdate dye mixture to each well. 
(Hint: ensure that the dye mixture is also added to the standard wells, as the 
change in absorbance within the standard curve is dependent on the interaction 
between the dye and the phosphate standard.) 
21. Allow for 30 minutes of colour development at room temperature before 
measuring standard and sample absorbance. Cover the well plate with a kimwipe. 
22. Measure absorbance in the plate reader at 600 nm. 
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Appendix 2: Calculations 
 
Appendix 2a. Dilution of Stock Insulin 
 
• Laboratory Application: whole skeletal muscle tissue incubations. 
 
• Details: incubations involve one experimental muscle (insulin + Medium 199) and 
one match–paired control from the same subject (Medium 199 only). 
 
• Product Name: Humilin® R U–100 
 
• Product Provider: local pharmacy 
 
• Stock Concentration: 100 units/mL 
 
• Desired Concentration: 10 milliunits/mL 
 
Table A2.1. Volume of stock insulin and Medium 199 required for application into whole 
skeletal muscle tissue incubations. 
 
Volume of 
Humilin–R  
(µL) 
Volume of 
Medium 199 
(µL) 
Total Volume 
(mL) 
Units of Insulin 
per mL 
Milliunits of 
Insulin per mL 
1000 0 1 100 100,000 
100 900 1 10 10,000 
10 990 1 1 1,000 
1 999 1 0.1 100 
0.1 999.9 1 0.01 10 
1.5 14998.5 15* 0.01 10 
*Tissue incubation reservoirs hold a total volume of 15 mL 
 
Laboratory Preparation 
 Prior to insulin–stimulated incubations, experimental tissue samples underwent 
30–minute equilibration incubations with Medium 199 only. For this equilibration period, 
experimental samples were incubated in 14 mL of Medium 199. During the equilibration 
period, a working solution was prepared containing 18 µL of Humilin–R and 11.982 mL 
of Medium 199 (1.5 µL Humilin–R per mL). This solution was prepared as an extension 
of the diluted insulin calculation presented in Table A2.1. Upon the conclusion of the 
equilibration period, 1 mL of the working solution was added to the incubation reservoir 
M.Sc. Thesis – J. R. Choptiany  Brock University 
 146 
in order to reach a final volume of 15 mL. Therefore, the incubating solution contained 
1.5 µL of Humilin–R resulting in an insulin concentration of 10 milliunits per mL, 
thereby satisfying the desired insulin concentration for experimental samples. 
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Appendix 2b. Dilution of Stock Kinase Inhibitor 
• Laboratory Application: used as a component of Chappell–Perry solutions and 
sucrose & mannitol buffer for the isolation of subsarcolemmal mitochondria. 
• Details: for the purpose of this study, it was deemed crucial to lock the 
phosphorylation state of all samples upon the conclusion of whole tissue 
incubations through the addition of kinase and phosphatase inhibitors. 
• Product Name: 7,8–dihydroxycoumarin 
• Product Provider: Sigma–Aldrich® 
• Molecular Weight: 178.14 g/M 
• Desired molarity: 200 µM 
Table A2.2. Molarity breakdown of stock kinase inhibitor required for application 
towards whole tissue homogenization procedures. 
 
Quantity of 
7,8–dihydroxycoumarin 
(mg) 
Final Volume of  
Working Solution 
(mL) 
Molarity 
178.14 1000 1 mM 
35.63 1000 200 µM 
3.56 100 200 µM 
0.356 10 200 µM 
 
Laboratory Preparation 
 
 The standard protocol for our lab when preparing working buffers for tissue 
homogenization procedures is to work with 10 mL aliquots from a larger stock solution. 
This is for practical reasons based upon the economical rationing of other products 
included in our homogenization buffers. 
 For the preparation of a 200 µM buffer with a final volume of 10 mL, only 0.356 
milligrams of kinase inhibitor is required. This is a difficult and impractical quantity to 
work with, which led towards the need for alternative preparation. Stock kinase inhibitor 
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arrives in 5 milligram quantities, which led to the decision to resuspend the entire vial in 
methanol (preferential solubility). As a result, a pre–calculated volume of resuspended 
kinase inhibitor could now be included in each 10 mL aliquot of working buffer. 
- 7,8–dihydroxycoumarin pack size: 5 mg 
- Quantity required per 10 mL at 200 µM: 0.356 mg 
- 5 ÷ 0.356 = 14.04 
 For every 5 milligram quantity of kinase inhibitor, the potential for 14 uses can be 
had when working at a concentration of 200 µM. Consequently, the entire vial was 
resuspended in 140.4 µL of methanol, which ensures a quantity of 0.356 milligrams per 
10 µL of methanol suspension. This suspension was prepared based upon the required 
200 µM concentration presented in Table A2.2. For every 10 mL aliquot of working 
homogenizing buffer, 10 µL of the 7,8–dihydroxycoumarin/methanol suspension was 
included in the final volume, thereby satisfying the required molarity to inhibit all kinase 
activity. 
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Appendix 2c. Determination of Anti–Phosphoserine Antibody Concentration 
• Laboratory Application: immunoprecipitation of serine phosphorylated proteins. 
• Details: through pilot testing it has been determined that both pyruvate 
dehydrogenase phosphatase isoforms are phosphorylated on serine residues within 
their polypeptide chains. 
• Product Name: Anti–Phosphoserine Polyclonal Antibody 
• Product Provider: Millipore™ 
• Stock Volume: 200 µL 
• Stock Concentration: 0.25 µg/µL 
Table A2.3. Volume of anti–phosphoserine antibody required to immunoprecipitate all 
serine–phosphorylated protein within tissue extracts. 
 
Volume of Antibody Applied 
to Immunoprecipitation 
(µL) 
Concentration of Antibody 
Applied to 
Immunoprecipitation 
(µg) 
Quantity of Precipitated 
Tissue Extract Protein 
(µg) 
200 50 2500 
40 10 500 
30 7.5 375 
20 5 250 
10 2.5 125 
 
Laboratory Preparation 
 For the analysis of serine–phosphorylated PDP1 and PDP2 protein content 
between basal and insulin–stimulated samples, all muscles were snap–frozen in liquid 
nitrogen following whole tissue incubations. Samples would then be homogenized in 
lysis buffer, and whole homogenate protein concentrations (µg/µL) would be determined 
via Bradford assay. Anti–phosphoserine polyclonal antibody would then be added to the 
muscle homogenates in order to precipitate phosphorylated PDP1 and PDP2 for 
comparative analysis between conditions via Western blotting. 
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 In order to properly demonstrate any change in phosphorylation between 
conditions, it was imperative to ensure that all phosphorylated proteins within a given 
sample were fully cleared. In other words, one would be unable to declare any change 
beyond a reasonable doubt if any phosphorylated PDP1 or PDP2 protein was not 
precipitated. Therefore, careful consideration was required to ensure that enough anti–
phosphoserine antibody was applied in order to satisfy this condition. 
 According to product information provided by Millipore™, 10–20 µg of antibody 
is required in order to immunoprecipitate all serine–phosphorylated proteins per 
milligram of whole tissue protein. Based upon the protein concentration of the antibody 
(0.25 µg/µL), this equates to 40–80 µL. From an economic standpoint, allocating 80 µL 
of antibody to every sample was deemed impractical. 
 In order to compensate for this demanding calculation, this immunoprecipitation 
method was piloted using 20 µL of anti–phosphoserine antibody in order to precipitate all 
phosphorylated proteins within 250 µg of whole muscle homogenate. Unfortunately, this 
compensation resulted in immunoprecipitated pellets that were too small to analyze 
adequately via Western blotting. Through further pilot testing, it was determined that 40 
µL of antibody and 500 µg of whole homogenate would suffice to execute this method 
successfully. Although this method was costly to execute, the final concentrations 
implemented in the PDP phosphorylation experiments were as cost–conscious as possible 
while still providing an opportunity for successful analysis. 
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Appendix 2d. Statistical Power 
• Thesis Application: determination of the minimum sample size required to 
evaluate the null hypothesis. 
• Details: studies conducted within the field of exercise physiology, and more 
specifically within our laboratory, typically involve 8 subjects per measure in 
order to evaluate research questions. 
Summary of Literature 
• Calculation of power is based upon the statistical test used to analyze a particular 
measurement 
- The only statistical tests used throughout the current study are T–tests, 
comparing the independent means of insulin–stimulated experimental 
groups and basal control groups 
• Calculation of the minimum sample size is dependent upon 3 factors: 
- The expected magnitude or effect size (ES) of a particular phenomenon 
- The significance criterion (alpha “α” level) used in the statistical test 
- Acceptable statistical power 
 Large effect sizes are typically expected within the field of exercise physiology 
- Large effect size for T–test analyses = 0.80 
 Traditional significance criteria are typically set at 0.01, 0.05, or 0.10 
- Criteria used throughout the current study = 0.05 
 Determination of appropriate sample size is based upon the default power setting 
- Acceptable statistical power = 0.80 
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According to the criteria mentioned above (ES of 0.80, alpha of 0.05, and power of 0.80), 
the minimum sample size required to evaluate the null hypothesis is 26 subjects per 
group. 
Conclusion 
 Although the literature recommends a minimum sample size of 26 for the 
measures in the current study (Cohen, 1992), this guideline could not be met. The 
reasoning behind this shortcoming is based upon the need for ethical and practical 
execution of the study. Firstly, our laboratory works in full cooperation with Brock 
University’s Animal Care and Use Committee. All animal work is performed with a 
commitment to study as few subjects as possible in order to conduct experiments. Under 
the guidance of my advisory committee, a sample size of 8 subjects per group, per 
measure has been deemed appropriate for the completion of my thesis. Secondly, all 
Master’s theses are structured with a 2–year timeframe for completion in mind. Under 
these limitations, performing the necessary experiments with a sample size of 26 is 
unreasonable. 
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Appendix 2e. PDH Activity Calculations 
• Laboratory Application: calculation of pyruvate dehydrogenase activity by the 
determination of acetyl–CoA concentration in whole muscle homogenates. 
• Details: this calculation involves data produced from two separate assays. First, 
whole homogenates undergo the PDHa activity assay, where varying amounts of 
endogenous acetyl–CoA are produced on an individual sample basis. PDHa 
samples are then processed further in the acetyl–CoA through the use of 
radiolabeled tagging in order to label and isolate intramuscular concentrations of 
endogenous acetyl–CoA. Both assays involve dilution phases, which must be 
accounted for with calculations in order to determine whole muscle enzyme 
activity rates. 
Dilution Factors 
All dilution factors are recorded as the quotient obtained by dividing the total volume of a 
given solution by the sample volume contained within a given solution. 
 DF1: homogenization of samples for the PDHa Assay (30–fold dilution). 
Total volume = 31 (30 µL of homogenizing buffer + 1 mg of tissue) 
Sample volume = 1 (1 mg of wet weight skeletal muscle tissue) 
DF1 = 31 
 DF2: incubation of homogenates and incubating solution for the PDHa Assay 
Total volume = 750 (720 µL of PDHa incubation solution + 30 µL of whole homogenate) 
Sample volume = 30 
DF2 = 26 
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 DF3: acidification and neutralization of samples following the PDHa Assay 
Total volume = 250 (200 µL of sample + 40 µL of acid + 10 µL of base) 
Sample volume = 200 (200 µL taken at 1, 2, and 3 minute intervals) 
DF3 = 1.25 
 DF4: incubation of PDHa samples and ddH2O for the Acetyl–CoA Assay 
Total volume = 220 (200 µL of ddH2O + 20 µL of neutralized PDHa sample) 
Sample volume = 20 
DF4 = 11 
 
PDHa Activity Calculation 
 
PDHa Activity (mmol acetyl–CoA  min–1  kg–1) = (Slope  DF1  DF2  DF3  DF4) 
         1000 
 
*Slope refers to the linear expression of acetyl–CoA measurements taken at 1, 2, and 3– 
minute intervals as part of the PDHa Assay. The slope, which represents the rate of the 
PDH reaction (rate of acetyl–CoA production), is calculated based upon each sample’s 
results from the acetyl–CoA assay. Please refer to the following appendices for additional 
information. 
 Appendix 1g: PDHa Activity Assay 
 Appendix 1h: Determination of Acetyl – CoA Accumulation 
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Appendix 2f. Citrate Synthase Calculations 
• Laboratory Application: calculation of maximal citrate synthase activity in whole 
muscle homogenates and mitochondrial suspensions. 
• Details: the determination of citrate synthase activity is performed in order to 
measure the mitochondrial recovery percentage following mitochondrial isolation 
procedures. Mitochondrial recovery values are then applied to experiments 
conducted using mitochondrial extracts as a normalizing control value. 
Calculation of Citrate Synthase 
1. Δ absorbance per minute  total reaction volume 
  sample volume  molar extinction coefficient 
 
2. CS Activity (µmol/min/g) = quotient of equation #1  tissue dilution factor 
Reaction Components 
• Δ absorbance per minute: determined by spectrophotometer following reaction 
• Total reaction volume: 250 µL (sample volume + reagent volumes) 
• Sample volume: 10 µL (regardless of sample specificity) 
• Molar extinction coefficient: 13,600 (specific for DTNB at 412 nm wavelength) 
• Tissue dilution factor: dependent upon specificity of sample 
- Whole homogenate (WH): 101 
- Total mitochondrial suspension (TS): 20 
 
Dilution Factor Calculations 
 
 Dilution Factor = total volume of solution 
    sample volume 
 
 Dilution Factor (WH)* = 101   Dilution Factor (TS)** = 100 
           1             5 
 
*Citrate Synthase homogenization calls for 100–fold dilution (1 mg/100 µL) 
**Total suspension = 5 µL mitochondrial extract + 95 µL sucrose & mannitol 
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Appendix 3: Citrate Synthase Activity Assay Raw Data 
 
Table A3. Citrate synthase activity assay raw data for basal and insulin–stimulated 
samples. 
 
Sample 
CSWH Activity 
(µmol/minute/g wet 
weight tissue) 
CSTS Activity 
(µmol/minute/g wet 
weight tissue) 
% Mitochondrial 
Recovery 
Basal 1 36.37 1.96 5.39 
Basal 2 21.20 2.52 11.89 
Basal 3 20.46 2.84 13.88 
Basal 4 33.38 3.85 11.53 
Basal 5 28.98 3.83 13.22 
Basal 6 31.62 2.64 8.35 
Basal 7 36.35 3.99 10.98 
Basal 8 26.40 2.72 10.30 
Basal 9 28.63 3.44 12.02 
Basal 10 29.50 3.35 11.36 
Insulin 1 27.00 2.14 7.93 
Insulin 2 30.93 2.82 9.12 
Insulin 3 25.27 3.28 12.98 
Insulin 4 31.90 3.94 12.35 
Insulin 5 30.11 1.38 4.58 
Insulin 6 24.95 3.81 15.27 
Insulin 7 30.82 4.55 14.76 
Insulin 8 28.42 3.74 13.16 
Insulin 9 31.54 3.52 11.16 
Insulin 10 31.17 2.93 9.40 
Mean 29.25 3.16 10.98 
Standard Error 0.94 0.18 0.64 
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Appendix 4: Components of Medium199 
 
Product Name: Medium199 – with Earle’s salts, L–glutamine, and sodium bicarbonate 
 
• Form: liquid 
• Impurities: endotoxin 
• Sterility: sterile–filtered 
• Suitability: cell culture 
• Storage temperature: 2–8° C 
 
Product Provider: Sigma–Aldrich® 
 
Product Code: M4530–500ML 
             
 
Components: M4530 [1X]     grams per Litre 
 
 Inorganic Salts 
 
o Calcium chloride dihydrate   0.2 
o Iron(III) nitrate nonahydrate   0.00072 
o Magnesium sulfate (anhydrous)  0.09767 
o Potassium chloride    0.4 
o Sodium acetate (anhydrous)   0.05 
o Sodium bicarbonate    2.2 
o Sodium chloride    6.8 
o Monosodium phosphate (anhydrous)  0.122 
 
 Amino Acids 
 
o L–alanine     0.025 
o L–arginine hydrochloride   0.07 
o L–aspartic acid    0.03 
o L–cystine hydrochloride monohydrate 0.00011 
o L–cysteine dihydrochloride   0.026 
o L–glutamic acid    0.0668 
o L–glutamine     0.1 
o Glycine     0.05 
o L–histidine hydrochloride monohydrate 0.02188 
o Hydroxy–L–proline    0.01 
o L–isoleucine     0.02 
o L–leucine     0.06 
o L–lysine hydrochloride   0.07 
o L–methionine     0.015 
o L–phenylalanine    0.025 
o L–proline     0.04 
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 Amino Acids continued…    g/L 
 
o L–serine     0.025 
o L–threonine     0.03 
o L–tryptophan     0.01 
o L–tyrosine disodium dihydrate  0.05766 
o L–valine     0.025 
 
 Vitamins 
 
o Sodium ascorbic acid    0.0000566 
o D–biotin     0.00001 
o Calciferol     0.0001 
o Choline chloride    0.0005 
o Folic acid     0.00001 
o Menadione (sodium bisulfite)   0.000016 
o Myo–inositol     0.00005 
o Niacinamide     0.000025 
o Nicotinic acid     0.000025 
o P–amino benzoic acid    0.00005 
o D–pantothenic acid hemicalcium  0.00001 
o Pyridoxal hydrochloride   0.000025 
o Pyridoxine hydrochloride   0.000025 
o Retinol acetate     0.00014 
o Riboflavin     0.00001 
o DL–α–tocopherol phosphate sodium  0.00001 
o Thiamine hydrochloride   0.00001 
 
 Other 
 
o Adenine sulfate    0.01 
o Adenosine triphosphate disodium  0.001 
o Adenosine monophosphate sodium  0.0002385 
o Cholesterol     0.0002 
o Deoxyribose     0.0005 
o Glucose     1.0 
o Glutathione (reduced)    0.00005 
o Guanine hydrochloride   0.0003 
o Hypoxanthine     0.0003 
o Phenol red sodium    0.0213 
o Tween 80     0.02 
o Ribose      0.0005 
o Thymine     0.0003 
o Uracil      0.0003 
o Xanthine sodium    0.000344 
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